Derma Sciences (DSCI) 10-K 13 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 12, 2014	Jun. 30, 2012
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'DERMA SCIENCES, INC.	'	'
Entity Central Index Key	'0000892160	'	'
Trading Symbol	'DSCI	'	'
Amendment Flag	'false	'	'
Document Type	'10-K	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'
Document Period End Date	31-Dec-13	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	25,131,673	'
Entity Public Float	'	'	$188,201,000

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets	'	'
Cash and cash equivalents	$6,501,586	$41,616,657
Short-term investments	15,478,000	3,730,000
Accounts receivable, net	7,332,756	7,085,713
Inventories	16,472,640	13,670,588
Prepaid expenses and other current assets	3,746,753	3,209,031
Total current assets	49,531,735	69,311,989
Long-term investments	7,858,140	498,000
Equipment and improvements, net	2,953,469	3,304,852
Identifiable intangible assets, net	14,635,998	17,128,883
Goodwill	13,457,693	13,457,693
Other assets	139,318	141,213
Total Assets	88,576,353	103,842,630
Current Liabilities	'	'
Accounts payable	4,522,508	3,993,687
Accrued expenses and other current liabilities	4,969,225	4,132,934
Total current liabilities	9,491,733	8,126,621
Long-term liabilities	242,325	268,517
Deferred tax liability	1,694,147	1,736,299
Total Liabilities	11,428,205	10,131,437
Commitments and Contingencies (note 14)	'	'
Stockholders' Equity	'	'
Convertible preferred stock, $.01 par value; 1,468,750 shares authorized; issued and outstanding 73,332 at December 31, 2013 and December 31, 2012 (liquidation preference of $3,222,368 at December 31, 2013)	733	733
Common stock, $.01 par value; 35,000,000 shares authorized; issued and outstanding 17,347,071 at December 31, 2013 and 16,524,723 at December 31, 2012	173,471	165,247
Additional paid-in capital	140,064,607	132,163,083
Accumulated other comprehensive income	1,080,148	1,588,888
Accumulated deficit	-64,170,811	-40,206,758
Total Stockholders' Equity	77,148,148	93,711,193
Total Liabilities and Stockholders' Equity	$88,576,353	$103,842,630

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Consolidated Balance Sheets [Abstract]	'	'
Convertible preferred stock, par value per share	$0.01	$0.01
Convertible preferred stock, shares authorized	1,468,750	1,468,750
Convertible preferred stock, shares issued	73,332	73,332
Convertible preferred stock, shares outstanding	73,332	73,332
Convertible preferred stock, liquidation preference	$3,222,368	'
Common stock, par value per share	$0.01	$0.01
Common stock, shares authorized	35,000,000	25,000,000
Common stock, shares issued	17,347,071	16,524,723
Common stock, shares outstanding	17,347,071	16,524,723

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements of Comprehensive Loss [Abstract]	'	'
Net Sales	$79,710,980	$72,648,198
Cost of sales	50,320,506	47,507,349
Gross Profit	29,390,474	25,140,849
Operating Expenses	'	'
Selling, general and administrative	42,044,484	32,485,368
Research and development	11,335,672	7,123,123
Total operating expenses	53,380,156	39,608,491
Operating loss	-23,989,682	-14,467,642
Other income, net	-185,740	-26,729
Loss before income taxes	-23,803,942	-14,440,913
Income tax provision (benefit)	160,111	-2,370,482
Net Loss	-23,964,053	-12,070,431
Other Comprehensive (Loss) Income	'	'
Foreign currency translation adjustment	-370,880	86,357
Unrealized loss on equity securities	-137,860	'
Total other comprehensive (loss) income	-508,740	86,357
Comprehensive Loss	($24,472,793)	($11,984,074)
Net loss per common share - basic and diluted	($1.40)	($0.97)
Shares used in computing net loss per common share - basic and diluted	17,056,632	12,488,263

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Convertible preferred stock [Member]	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning balance at Dec. 31, 2011	$50,847,534	$733	$105,776	$77,374,821	$1,502,531	($28,136,327)
Beginning balance, shares at Dec. 31, 2011	'	73,332	10,577,632	'	'	'
Net loss	-12,070,431	'	'	'	'	-12,070,431
Foreign currency translation adjustment	86,357	'	'	'	86,357	'
Unrealized loss on investment	'	'	'	'	'	'
Issuance of common stock, net of issuance costs	51,461,053	'	56,463	51,404,590	'	'
Issuance of common stock, net of issuance costs, shares	5,646,300	'	5,646,300	'	'	'
Shares withheld for minimum payroll taxes	-80,550	'	'	-80,550	'	'
Exercise of warrants and options, net of issuance costs	1,225,620	'	2,552	1,223,068	'	'
Exercise of warrants and options, net of issuance costs, shares	255,210	'	255,210	'	'	'
Vesting of restricted stock units	'	'	431	-431	'	'
Vesting of restricted stock units, shares	43,081	'	43,081	'	'	'
Issuance of common stock	'	'	25	-25	'	'
Issuance of common stock, shares	2,500	'	2,500	'	'	'
Stock-based compensation	2,241,610	'	'	2,241,610	'	'
Ending balance at Dec. 31, 2012	93,711,193	733	165,247	132,163,083	1,588,888	-40,206,758
Ending balance, shares at Dec. 31, 2012	'	73,332	16,524,723	'	'	'
Net loss	-23,964,053	'	'	'	'	-23,964,053
Foreign currency translation adjustment	-370,880	'	'	'	-370,880	'
Unrealized loss on investment	-137,860	'	'	'	-137,860	'
Shares withheld for minimum payroll taxes	-228,149	'	'	-228,149	'	'
Exercise of warrants and options, net of issuance costs	2,817,001	'	5,568	2,811,433	'	'
Exercise of warrants and options, net of issuance costs, shares	556,855	'	556,855	'	'	'
Vesting of restricted stock units	'	'	1,210	-1,210	'	'
Vesting of restricted stock units, shares	120,957	'	120,957	'	'	'
Issuance of common stock	'	'	45	-45	'	'
Issuance of common stock, shares	4,450	'	4,450	'	'	'
Stock-based compensation	5,320,896	'	'	5,320,896	'	'
Preferred stock reset (note 10)	'	'	1,401	-1,401	'	'
Preferred stock reset (note 10), shares	140,086	'	140,086	'	'	'
Ending balance at Dec. 31, 2013	$77,148,148	$733	$173,471	$140,064,607	$1,080,148	($64,170,811)
Ending balance, shares at Dec. 31, 2013	'	73,332	17,347,071	'	'	'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements of Stockholders' Equity [Abstract]	'	'
Issuance of common stock, issuance costs	'	$4,605,439
Exercise of warrants and options, issuance costs	$45,368	$10,560

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Operating Activities	'	'
Net loss	($23,964,053)	($12,070,431)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation of equipment and improvements	878,151	1,021,402
Amortization of identifiable intangible assets	2,842,885	2,274,161
Provision for bad debts	43,930	49,492
Allowance for sales adjustments	38,257	69,091
Provision for inventory obsolescence	7,317	350,798
Loss on disposal of equipment	11,917	31,424
Deferred rent	-13,215	9,491
Stock based compensation	5,320,896	2,241,610
Deferred income taxes	132,156	-2,507,355
Changes in operating assets and liabilities:	'	'
Accounts receivable	-266,828	-329,962
Inventories	-3,042,090	-3,265,213
Prepaid expenses and other current assets	-589,842	-812,983
Other assets	-77,023	-4,535
Accounts payable	574,347	-399,919
Accrued expenses and other current liabilities	901,038	1,438,656
Net cash used in operating activities	-17,202,157	-11,904,273
Investing Activities	'	'
Investment in acquired business, net of cash acquired	'	-14,357,578
Purchase of investments	-33,723,000	-6,469,000
Proceeds from sale of investments	14,477,000	7,715,000
Purchase of equipment and improvements	-695,776	-826,208
Purchase of intangible assets	-350,000	-2,300,000
Proceeds from sale of equipment	'	47,215
Net cash used in investing activities	-20,291,776	-16,190,571
Financing Activities	'	'
Proceeds from the sale of common stock, net of costs	'	51,461,053
Proceeds from exercise of stock options and warrants, net of costs	2,817,001	1,225,620
Payment of withholding taxes related to employee stock compensation	-228,149	-80,550
Net cash provided by financing activities	2,588,852	52,606,123
Effect of exchange rate changes on cash	-209,990	-4,972
Net (decrease) increase in cash and cash equivalents	-35,115,071	24,506,307
Cash and cash equivalents	'	'
Beginning of year	41,616,657	17,110,350
End of year	6,501,586	41,616,657
Cash paid during the year for:	'	'
Interest	893	2,200
Taxes	'	'

Description_of_Business

Description of Business	12 Months Ended
	Dec. 31, 2013
Description of Business [Abstract]	'
Description of Business	'
	1	Description of Business
	Derma Sciences, Inc. and its subsidiaries (the "Company") is a tissue regeneration company focused on three segments of the wound care marketplace: advanced wound care, traditional wound care and pharmaceutical wound care products. The Company has one drug candidate that initiated its Phase 3 study during the first quarter of 2013. The Company markets its products principally through direct sales representatives in the United States ("U.S."), Canada and the United Kingdom ("U.K."), and through independent distributors within other select international markets. The Company's U.S. distribution facilities are located in St. Louis, Missouri and Houston, Texas. The Company utilizes third party distributors for distribution in Canada, Europe and the Far East. The Company has manufacturing facilities in Toronto, Canada and Nantong, China.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
		2	Summary of Significant Accounting Policies
	Principles of Consolidation - The consolidated financial statements include the accounts of Derma Sciences, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates - The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on knowledge of current events and actions which may be undertaken in the future, actual results may ultimately differ from these estimates. Estimates and assumptions are required in the determination of sales deductions for trade rebates, sales incentives, discounts and allowances. Significant estimates and assumptions are also required in determining the appropriateness of amortization periods for identifiable intangible assets, the potential impairment of goodwill and the valuation of inventory.
	Foreign Currency Translation - Assets and liabilities are translated using the exchange rates in effect at the balance sheet date, while income and expenses are translated using average rates during the period. Translation adjustments are reported as a component of stockholders' equity in accumulated other comprehensive income. For the Company's foreign subsidiaries, exchange rate fluctuations on foreign currency denominated assets and liabilities other than the functional currency resulted in income of $140,721 and $47,738 for the years ended December 31, 2013 and 2012, respectively, which is included in the Consolidated Statement of Comprehensive Loss as follows:
			2013			2012
	Cost of sales		$	57,894		$	7,031
	Other income, net			(198,615	)		(54,769	)
	Total		$	(140,721	)	$	(47,738	)
	Exchange rate fluctuations of foreign currency denominated assets and liabilities associated with inventory are included in cost of sales, while all other such fluctuations are included in other income, net.
	Concentration of Credit Risk - Financial instruments that subject the Company to a concentration of credit risk consist principally of cash and cash equivalents, investments in debt securities and accounts receivable. The Company maintains cash and cash equivalents with various financial institutions in amounts which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts. The Company does not require collateral or other security to support credit sales, but provides an allowance for doubtful accounts based on historical experience and specifically identified risks. Accounts receivable are charged off against the allowance for doubtful accounts when management determines that recovery is unlikely and the Company ceases collection efforts.
	Inventories - Inventories consist of raw materials, packaging materials, work in process and finished goods valued at the lower of cost or market. Cost is determined on the basis of the first-in, first-out method.
	Equipment and improvements - Equipment and improvements are stated at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets ranging from three to 10 years. Leasehold improvements are amortized over the lesser of their useful lives or the remaining lease term.
	Fair Value of Financial Instruments - The carrying value of cash equivalents, accounts receivable, prepaid expenses and other current assets, and accounts payable reported in the consolidated balance sheets equal or approximate fair value due to their short term nature.
	Identifiable Intangible Assets - Identifiable intangible assets, which consist of product license rights, developed technology and supply agreements, and other identifiable intangible assets, are amortized over one to 13 years on a straight-line basis.
	Long Lived Assets -The Company reviews its long-lived assets with definitive lives whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If the carrying amount of the asset or group of assets exceeds its net realizable value, the asset will be written down to its fair value.
	Goodwill - The Company tests goodwill for impairment using a two-step process. The first step tests for potential impairment, while the second step measures the amount of impairment, if any. The Company uses a discounted cash flow analysis to complete the first step in this process. If the first step indicates an impairment, i.e. when the carrying value exceeds the fair value, then the second step is required to determine the implied fair value of goodwill. The implied fair value of goodwill is calculated in the same manner that goodwill is calculated in a business combination. The allocation is to be performed as if the reporting unit had just been acquired and the fair value of the unit was the purchase price. The goodwill impairment equals the carrying value of goodwill less the implied fair value of goodwill. The Company performs its goodwill impairment test as of December 31st of each year, or more frequently if impairment indicators are present.
	Stock-Based Compensation - Stock-based compensation for share-based awards with employees and non-employee directors, such as grants of stock options and restricted share units, are recognized in the consolidated financial statements based on the fair value of the award at the grant date on a straight-line basis over the requisite service or performance periods. Stock-based compensation for share-based awards granted to consultants are recognized based on the fair value of the award on a straight-line basis over the requisite service or performance periods and are revalued at the end of each period until the award vests. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model for service and performance based awards. The fair value of restricted share units is based on the quoted market price for service and performance based awards, and by using a binomial/lattice pricing model for market based awards. The Company issues new common stock shares upon exercise of share-based awards.
	Income Taxes - Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets, including tax loss and credit carryforwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of income tax positions is recognized only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.
	The Company measures and recognizes the tax implications of positions taken or expected to be taken in its tax returns on an ongoing basis. In 2013 and 2012, the Company had no unrecognized tax benefits or liabilities, and no adjustment to its financial position, results of operations or cash flows were required. The Company records interest and penalties related to tax matters within other income, net on the accompanying Consolidated Statements of Comprehensive Loss. These amounts are not material to the consolidated financial statements for the periods presented. The Company's U.S. tax returns are subject to examination by federal and state taxing authorities. Tax years prior to 2010 are no longer subject to federal examination. However, the Company's federal net operating losses for tax years 1999 through 2009 will remain subject to examination until the losses are utilized or expire. State tax years 2009 to 2013 remain open to examination by the various state jurisdictions in which the Company is subject to tax. Tax years prior to 2005 are no longer subject to examination in Canada. The U.K. tax returns since the inception of the subsidiary in 2010 are subject to examination.
	Revenue Recognition - Sales are recorded when product is shipped or title passes to customers and collectability is reasonably assured. Gross sales are adjusted for cash discounts, returns and allowances, trade rebates, distribution fees (in Canada) and other sales deductions in the same period that the related sales are recorded. Freight costs billed to and reimbursed by customers are recorded as a component of revenue. Freight costs to ship product to customers are recorded as a component of cost of sales.
	Advertising and Promotion Costs - Advertising and promotion costs are charged to expense as incurred and were $3,082,221 and $2,243,387 in 2013 and 2012, respectively.
	Royalties - The Company recognizes royalty expenses associated with the products sold at the time the related sale occurs and records them as a component of cost of sales. Royalty expense for the years ended December 31, 2013 and 2012 was $1,741,742 and $1,395,567, respectively.
	Net Loss per Share - Net loss per common share - basic is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Net loss per common share - diluted reflects the potential dilution of earnings by including the effects of the assumed exercise, conversion or issuance of potentially issuable shares of common stock ("potentially dilutive securities"), including those attributable to stock options, warrants, convertible preferred stock and restricted share units in the weighted average number of common shares outstanding for a period, if dilutive. The effects of the assumed exercise of warrants and stock options are determined using the treasury stock method. Potentially dilutive securities have not been included in the computation of diluted loss per share for the years ended December 31, 2013 and 2012 as the effect would be anti-dilutive.
	Potentially dilutive shares excluded as a result of the effects being anti-dilutive are as follows:
			Year Ended December 31,
			2013			2012
	Excluded dilutive shares:
	Convertible preferred stock			73,332			73,332
	Additional stock issuable related
	to conversion of preferred stock			49,154			-
	Restricted share units			720,550			786,900
	Stock options			1,814,233			1,639,985
	Warrants			2,305,272			2,930,154
	Total dilutive shares			4,962,541			5,430,371
	Recently Issued Accounting Pronouncements - In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, which requires companies to present information about reclassifications out of accumulated other comprehensive income in a single note or on the face of the financial statements. The updated standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2012, with early adoption permitted. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2013
Acquisition [Abstract]	'
Acquisition	'
		3	Acquisition
	On April 16, 2012, the Company acquired all of the outstanding stock of MedEfficiency, Inc. ("MedEfficiency") pursuant to the terms of an Agreement and Plan of Merger. The purchase price was $14,475,000 and was funded by the Company with cash on hand. The Company incurred transaction and transition related costs totaling $1,256,853 related to the purchase, which were charged to selling, general and administrative expense in the 2012 Consolidated Statement of Comprehensive Loss.
	MedEfficiency develops, manufactures and markets medical devices for treating chronic wounds and lower extremity injuries, specializing in total contact casting ("TCC") products. The TCC-EZ total contact cast system is MedEfficiency's lead product, in addition to a line of traditional and specialized contact casts and related equipment. The Company has distributed MedEfficiency's TCC products since 2008 under an exclusive distribution agreement.
	The acquisition has been accounted for as a purchase. Accordingly, the results of operations of MedEfficiency have been included in the consolidated financial statements commencing April 17, 2012. The allocation of the purchase price to the estimated fair value of the assets acquired and the liabilities assumed is outlined below:
	Current assets		$	925,817
	Equipment			29,579
	Acquired intangible assets			10,700,000
	Goodwill			6,337,967
	Total assets acquired			17,993,363
	Current liabilities			653,315
	Deferred tax liability			2,982,470
	Total liabilities assumed			3,635,785
	Net assets acquired		$	14,357,578
	Purchase price		$	14,475,000
	Less cash acquired			117,422
	Net cash paid		$	14,357,578
	The allocation of the purchase price to the assets acquired and liabilities assumed was based on an independent valuation study to establish the fair value of the identifiable intangible assets acquired. The identifiable intangible assets acquired consist of developed technology and patents, customer relationships, a supply agreement, trade names and trademarks and non-compete agreements. The Company recorded the excess of the purchase price over the fair values of the identifiable assets acquired and liabilities assumed as goodwill. While the acquired intangible assets are amortizable for financial reporting purposes, the acquired intangible assets and goodwill are not deductible for tax purposes. Deferred taxes have been recorded associated with the acquisition for the basis differences for financial reporting and income tax purposes for the acquired identifiable intangible assets at the effective tax rates for the period in which the deferred tax asset and liability are expected to reverse. All of the assets acquired, including goodwill, and liabilities assumed are included in the Advanced Wound Care segment.
	The unaudited pro forma information below presents combined results of operations as if the acquisition had occurred at the beginning of the periods presented instead of April 16, 2012. The pro forma information is based on historical results adjusted for the effect of purchase accounting and is not necessarily indicative of the results of operations of the combined entity had the acquisition occurred at the beginning of the periods presented, nor is it necessarily indicative of future results.
			Year ended,
			31-Dec-12
			(Unaudited)
	Net Sales		$	74,035,688
	Net Loss		$	(12,762,551	)
	Net Loss per common share -
	basic and diluted		$	(1.02	)
	Weighted average number of shares -
	basic and diluted			12,488,263

Cash_and_Cash_Equivalents_and_

Cash and Cash Equivalents and Investments	12 Months Ended
	Dec. 31, 2013
Cash and Cash Equivalents and Investments [Abstract]	'
Cash and Cash Equivalents and Investments	'
		4	Cash and Cash Equivalents and Investments
	Cash and Cash Equivalents
	The Company considers cash and cash equivalents as amounts on hand, on deposit in financial institutions and highly liquid investments purchased with an original maturity of three months or less. Money market mutual funds consist of funds deposited into mutual funds investing in U.S. government and non-government obligations. The Company maintains cash and cash equivalents and money market mutual funds with various domestic and foreign financial institutions within the ordinary course of business, which at times may exceed jurisdictional insurance limits.
	Investments in debt securities
	Investments in debt securities includes certificates of deposit purchased with an original maturity greater than three months which are deposited in various U.S. financial institutions and are fully insured by the Federal Deposit Insurance Corporation. The Company intends to hold the certificates of deposit to maturity and accordingly these investments are carried at amortized cost. Investments in debt securities with maturities greater than one year from the balance sheet date are classified as a long-term asset.
	Investment in equity securities
	In 2013, the Company purchased 2,272,277 shares of Comvita Limited ("Comvita") common stock for $7,000,000. The equity investment represented 7.3% of Comvita's outstanding shares on the date of purchase. In conjunction with this investment, the Company's chairman and chief executive officer was named to Comvita's board of directors. Comvita will use the proceeds from this investment to purchase additional apiaries and upgrade and expand its Manuka honey processing capabilities. This investment will assist Comvita in its effort to better ensure supply for the Company's medical-grade honey requirements in an environment of growing global demand for Manuka honey.
	The investment in Comvita common stock is classified as an available-for-sale investment carried at fair value, with any unrealized gains and losses associated with the investment included in accumulated other comprehensive income and any dividends received recorded in other income. The investment is classified as a long term asset. As of December 31, 2013, the fair value of the Comvita common stock was $6,862,140 as determined by the quoted market price of the outstanding stock on the New Zealand stock exchange. The $137,860 decrease in fair value from cost was recorded in accumulated other comprehensive income. In December 2013, Comvita declared a dividend, the Company's share of which was $75,421, net of taxes.
	Cash and cash equivalents and investments at December 31, 2013 and 2012 consisted of the following:
			December 31,
			2013		2012
	Cash		$	5,265,903	$	4,909,663
	Money market mutual funds			1,235,683		36,706,994
	Cash and cash equivalents			6,501,586		41,616,657
	Investments in debt securities			16,474,000		4,228,000
	Investment in equity securities			6,862,140		-
	Total investments			23,336,140		4,228,000
	Total cash and cash equivalents and investments		$	29,837,726	$	45,844,657
	The following table provides fair value information as of December 31, 2013:
					Fair Value Measurements, Using
			Total carrying		Quoted prices		Significant other		Significant
			value as of		in active		observable		unobservable
			31-Dec-13		markets		inputs		inputs
					(Level 1)		(Level 2)		(Level 3)
	Cash and cash equivalents		$	6,501,586	$	6,501,586	$	-	$	-
	Investments in debt securities			16,474,000		16,463,473		-		-
	Investment in equity securities			6,862,140		6,862,140		-		-
	Total Investments			23,336,140		23,325,613		-		-
	Total		$	29,837,726	$	29,827,199	$	-	$	-
	The following table provides fair value information as of December 31, 2012:
					Fair Value Measurements, Using
			Total carrying		Quoted prices		Significant other		Significant
			value as of		in active		observable		unobservable
			31-Dec-12		markets		inputs		inputs
					(Level 1)		(Level 2)		(Level 3)
	Cash and cash equivalents		$	41,616,657	$	41,616,657	$	-	$	-
	Investments in debt securities			4,228,000		4,216,156		-		-
	Total		$	45,844,657	$	45,832,813	$	-	$	-
	Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets. Level 2 inputs are quoted prices for similar assets in active markets or inputs that are observable for the asset, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management's own assumptions used to measure assets at fair value. A financial asset's classification is determined based on the lowest level input that is significant to the fair value measurement.

Accounts_Receivable_net

Accounts Receivable, net	12 Months Ended
	Dec. 31, 2013
Accounts Receivable, net [Abstract]	'
Accounts receivable, net	'
		5	Accounts Receivable, net
	Accounts receivable, net includes the following:
			December 31,
			2013			2012
	Accounts receivable		$	7,781,482		$	7,557,862
	Less: Allowance for doubtful accounts			(97,729	)		(147,843	)
	Allowance for trade rebates			(218,700	)		(197,650	)
	Allowance for cash discounts and returns			(132,297	)		(126,656	)
	Accounts receivable, net		$	7,332,756		$	7,085,713

Inventories

Inventories	12 Months Ended
	Dec. 31, 2013
Inventories [Abstract]	'
Inventories	'
	6	Inventories
	Inventories include the following:
			December 31,
			2013		2012
	Finished goods		$	11,044,746	$	9,574,685
	Work in process			1,009,315		554,129
	Packaging materials			1,408,521		991,157
	Raw materials			3,010,058		2,550,617
	Total inventory		$	16,472,640	$	13,670,588

Equipment_and_Improvements_net

Equipment and Improvements, net	12 Months Ended
	Dec. 31, 2013
Equipment and Improvements, net [Abstract]	'
Equipment and Improvements, net	'
		7	Equipment and Improvements, net
	Equipment and improvements, net include the following:
			December 31,
			2013			2012
	Machinery and equipment		$	7,102,144		$	7,135,714
	Furniture and fixtures			911,879			843,149
	Leasehold improvements			2,300,500			2,226,022
				10,314,523			10,204,885
	Less: accumulated depreciation			(7,361,054	)		(6,900,033	)
	Total equipment and improvements, net		$	2,953,469		$	3,304,852

Identifiable_Intangible_Assets

Identifiable Intangible Assets, net	12 Months Ended
	Dec. 31, 2013
Identifiable Intangible Assets, net [Abstract]	'
Identifiable Intangible Assets, net	'
	8	Identifiable Intangible Assets, net
	Costs of identifiable intangible assets associated with previous acquisitions, as well as payments in connection with obtaining product license rights, are included as identifiable intangible assets. During 2013, the Company paid $250,000 associated with Medihoney developed technology and $100,000 associated with the international TCC-EZ supply agreement.
	Identifiable intangible assets, net include the following:
			December 31,						Amortization Period
			2013			2012
	Product license rights		$	8,217,126		$	7,967,126		6-10 years
	Developed technology and supply agreements			7,700,000			7,600,000		5-7 years
	Other			6,400,000			6,400,000		1-10 years
				22,317,126			21,967,126
	Less accumulated amortization			(7,681,128	)		(4,838,243	)
	Total identifiable intangible assets, net		$	14,635,998		$	17,128,883
	During the years ended December 31, 2013 and 2012, amortization expense was recorded as follows:
			2013			2012
	Cost of sales		$	2,009,472		$	1,461,411
	Selling, general and administrative expenses			833,413			812,750
	Total amortization expense		$	2,842,885		$	2,274,161
	Amortization expense for product license rights and developed technology and supply agreements is included as a component of cost of sales and amortization of other identifiable intangible assets is included in selling, general and administrative expense in the Consolidated Statement of Comprehensive Loss.
	Amortization expense for 2013 and 2012 and estimated amounts thereafter by year are as follows:
			Product License Rights			Developed			Other		Total
						Technology and Supply Agreements
	Amortization expense for		$	908,758		$	1,100,714		$	833,413	$	2,842,885
	year ended December 31, 2013
	Weighted Average Useful Life			6			5.3			3.2		4.8
	Amortization expense for		$	692,363		$	769,048		$	812,750	$	2,274,161
	year ended December 31, 2012
	Estimated amortization expense for years ending December 31,
	2014		$	946,613		$	1,105,715		$	775,000	$	2,827,328
	2015			946,613			1,105,715			775,000		2,827,328
	2016			946,613			1,105,715			626,250		2,678,578
	2017			946,613			1,105,715			281,667		2,333,995
	2018			946,613			1,025,295			165,000		2,136,908
	Thereafter			987,990			382,083			461,788		1,831,861
			$	5,721,055		$	5,830,238		$	3,084,705	$	14,635,998

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities [Abstract]	'
Accrued Expenses and Other Current Liabilities	'
	9	Accrued Expenses and Other Current Liabilities
	Accrued expenses and other current liabilities include the following:
			December 31,
			2013		2012
	Accrued compensation and related taxes		$	2,529,211	$	1,929,524
	Accrued Canadian sales rebate, net (note 14)			252,671		636,633
	Accrued royalties			361,559		427,075
	Accrued sales incentives and other fees			546,296		316,209
	Other			1,279,488		823,493
	Total accrued expenses and other current liabilities		$	4,969,225	$	4,132,934
	At December 31, 2013 and 2012, the amount of the Canadian accrued sales rebate and other reserves exceeded the amount of the underlying trade receivables outstanding. The net credit balance in trade receivables was reclassified for financial reporting purposes to accrued expense to recognize it as a net liability.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
		10	Stockholders' Equity
	Preferred Stock
	There are 18,598 shares of series A convertible preferred stock outstanding at December 31, 2013. The series A preferred stock is convertible into common stock on a one-for-one basis, bears no dividend, has a liquidation preference of $32.00 per share, votes as a class on matters affecting the series A preferred stock and has voting rights identical to the common stock on all other matters.
	There are 54,734 shares of series B convertible preferred stock outstanding at December 31, 2013. The series B preferred stock is convertible into common stock on a one-for-one basis, bears no dividend, has a liquidation preference of $48.00 per share, votes as a class on matters affecting the series B preferred stock and has voting rights identical to the common stock on all other matters.
	The certificates of designations, voting powers, preferences and rights of the Company's series A and B and former C and D convertible preferred stock provide, among other items, that the 1:1 preferred stock to common stock conversion ratio will be adjusted as of the closing date of any offering of common stock issued at less than the prevailing market price. In the event the market price exceeds the offering price of the common stock, the conversion ratios of any series of preferred stock then outstanding are to be adjusted in accordance with a prescribed formula.
	Subsequent to the issuances of the preferred stock, the Company has undertaken a number of common stock offerings that would impact the above described adjustments to the preferred stock conversion ratios. As of December 31, 2013, current series A and B preferred stockholders holding 73,332 preferred shares are entitled to receive an aggregate of 121,089 shares (47,757 additional shares) of common stock upon conversion of their holdings, as a result of the conversion ratio adjustments. The number of shares issuable upon conversion is subject to further adjustment should the Company in the future undertake one or more offerings of its common stock at less than the prevailing market price. Previous preferred stockholders who have converted their preferred shares will receive an additional 1,397 shares of common stock as a result of the conversion ratio adjustments. In 2013 the Company issued 140,086 common shares to prior holders of the preferred stock based on the adjustment of the conversion ratios.
	The 49,154 incremental shares associated with the conversion ratio adjustment will be recorded to common stock at par with the offset to additional paid in capital as all of the convertible preferred stock was issued prior to the November 16, 2000 effective date of certain provisions of ASC 470 (formerly, EITF 00-27 Application of Issue No. 98-5 to Certain Convertible Instruments).
	Common Stock
	On May 22, 2013, stockholders of the Company approved the proposal to increase the number of authorized shares of common stock from 25,000,000 to 35,000,000. On May 29, 2013, the Company amended its Articles of Incorporation to reflect the increase in the number of authorized shares of common stock.
	During 2013, the Company issued 822,348 shares of common stock consisting of 556,855 shares upon the exercise of stock purchase warrants and options for which the Company received $2,817,001 (net of $45,368 in expenses), 140,086 shares in connection with the preferred stock ratio adjustments, 120,957 shares in connection with the vesting of 145,650 shares of restricted common stock units net of the shares withheld for payment of withholding taxes, and 4,450 shares to a retired director of the Company for consulting services.
	In 2012, the Company received net cash proceeds of $51,461,053 (net of $4,605,439 in commission and other offering expenses) from the sale of 5,646,300 shares of common stock. On April 5, 2012, 2,125,000 common stock shares were sold at $9.25 per share and on December 5, 2012, 3,521,300 common stock shares were sold at $10.34 per share. The Company used and intends to continue to use the net proceeds from the offerings for the continued development of its pharmaceutical product DSC127 and for general corporate purposes.
	During 2012, the Company issued 255,210 shares of common stock upon the exercise of stock purchase warrants and options and received $1,225,620 (net of $10,560 in issuance costs); 43,081 net shares of common stock in connection with the vesting of 51,500 shares of restricted stock units, net of the shares withheld for payment of minimum withholding taxes; and 2,500 shares of common stock to a retiring director of the Company for past services.
	Stock Purchase Warrants
	At December 31, 2013, the Company had warrants outstanding to purchase shares of the Company's common stock consisting of the following:
	Series		Number of Warrants			Exercise Price			Expiration Date
	L			6,250		$	3.12		31-Mar-14
	N			100,000		$	6.25		22-Feb-15
	O			230,900		$	5.5		22-Feb-15
	P			2,187		$	6.25		16-Feb-15
	Q			133,333		$	5.5		22-Feb-15
	R			1,832,602		$	9.9		22-Jun-16
	Total		$	2,305,272
	During 2013, a total of 624,882 warrants were exercised on a for cash and cashless basis consisting of 367,814 Series K, 200,893 Series J, 53,667 Series O, and 2,508 Series P warrants. A total of 421,465 shares of common stock were issued in connection with the 2013 warrant exercises. In 2012 a total of 135,548 warrants were exercised on a cash basis consisting of 47,333 series O, 66,965 series J and 21,250 series K warrants. A total of 135,548 shares of common stock were issued in connection with the 2012 warrant exercises.
	Equity Based Compensation
	Under the Derma Sciences, Inc. 2012 Equity Incentive Plan (the "EIP Plan") the Company is authorized to issue shares of common stock. On May 22, 2013, stockholders of the Company approved the proposal to increase the number of authorized shares of common stock the Company can issue from 2,812,500 to 4,500,000. The EIP Plan authorizes the Company to grant equity-based and cash-based incentive compensation in the form of stock options, stock appreciation rights, restricted shares, restricted share units, other share-based awards and cash-based awards, for the purpose of providing the Company's employees, non-employee directors and consultants with incentives and rewards for performance. At December 31, 2013, options to purchase 1,814,233 shares and 720,550 restricted share units were issued and outstanding under the EIP Plan and 1,394,480 shares were available for grant.
	Stock Options
	The EIP Plan permits the granting of both incentive and nonqualified stock options to employees and nonqualified stock options to non-employee directors and consultants of the Company. The option exercise price may not be less than the fair market value of the stock on the date of the grant of the option. The duration of each option may not exceed 10 years from the date of grant.
	For the years ended December 31, 2013 and 2012, the fair value of each option award was estimated at the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions for the years ended December 31, 2013 and 2012 were as follows:
			2013			2012
	Risk-free interest rate			1.22	%		1.11	%
	Volatility factor			69.9	%		73.6	%
	Dividend yield			0	%		0	%
	Expected option life (years)			6.14			6.25
	The risk-free rate utilized represents the U.S. treasury yield curve rate for the expected option life at the time of grant. The volatility factor was calculated based on the Company's historical stock price volatility equal to the expected life of the option at the grant date. The dividend yield is 0% since the Company does not anticipate paying dividends in the near future. The simplified expected option life method is used to determine the expected option life for Company employees and directors while the contractual option life period is utilized for consultants.
	Based on the Company's historical experience of options that were forfeited before becoming fully vested, the Company has assumed an annualized forfeiture rate of 1.0% for all options. The Company will record additional expense if the actual forfeiture rate is lower than estimated, and will record a recovery of prior expense if the actual forfeiture rate is higher than estimated.
	A summary of the Company's stock option activity and related information for the years ended December 31, 2013 and 2012 follows:
			2013						2012
			Options			Weighted Average Exercise Price			Options			Weighted Average Exercise Price
	Outstanding - beginning of year			1,639,985		$	6.38			1,582,683		$	5.82
	Granted			421,480		$	12.14			268,160		$	8.93
	Forfeited			(36,878	)	$	10.99			(61,825	)	$	7.53
	Exercised			(184,824	)	$	5.5			(149,033	)	$	4.37
	Expired			(25,530	)	$	13.16			-			-
	Outstanding - end of year			1,814,233		$	7.67			1,639,985		$	6.38
	Expected to vest - end of year			1,796,091		$	7.67			1,623,585		$	6.38
	Exercisable at end of year			1,443,409		$	6.84			1,208,077		$	5.86
	During 2013 and 2012, the Company granted 300,880 and 199,460 service based options and 120,600 and 68,700 performance based options to Company employees, directors and consultants, respectively. The weighted average fair value per share of options granted during the years ended December 31, 2013 and 2012 was $8.30 and $5.93, respectively.
	During 2013, 184,824 stock options were exercised on a for cash and cashless basis. A total of 135,390 shares of common stock were issued in connection with the 2013 stock option exercises. During 2012, 149,033 stock options were exercised on a for cash or cashless basis. A total of 119,662 common stock shares were issued in connection with the 2012 stock option exercises.
	The aggregate intrinsic value of outstanding and exercisable stock options was $6,287,268 and $5,967,544, respectively, at December 31, 2013. The intrinsic value represents the difference between the Company's closing stock price on the last trading day of the year of $10.82 and the exercise price of the options, multiplied by the number of in-the-money stock options that would have been received by the option holders had all exercised their options on December 31, 2013. The intrinsic value of options exercised in 2013 and 2012 was $1,286,818 and $792,315, respectively.
	The following table summarizes information related to stock options outstanding and exercisable at December 31, 2013:
			Options Outstanding									Options Exercisable
	Range of		Number Outstanding			Weighted-Average Remaining Contractual Life			Weighted-Average Exercise Price			Number Exercisable		Weighted-Average Exercise Price
	Exercise Prices
	$2.88 - $4.00			251,961			3.38		$	3.43			251,961	$	3.43
	$4.01 - $6.00			473,412			5.18		$	5.13			463,912	$	5.13
	$6.01 - $10.00			610,470			6.77		$	8.03			500,799	$	7.95
	$10.01 - $13.99			478,390			8.59		$	11.97			226,737	$	11.66
				1,814,233			6.36		$	7.67			1,443,409	$	6.84
	During the years ended December 31, 2013 and 2012, stock option compensation expense was recorded as follows:
			2013			2012
	Cost of sales		$	95,726		$	39,789
	Selling, general and administrative expenses			2,087,827			1,470,269
	Research and development			165,581			103,289
Total stock option compensation expense		$	2,349,134		$	1,613,347
As of December 31, 2013, there was $1,645,272 of unrecognized compensation cost related to non-vested service based awards granted under the plan. These costs are expected to be recognized over the options' remaining weighted average vesting period of 1.91 years. There was no unrecognized compensation cost related to non-vested performance based awards at December 31, 2013.
Restricted Share Units
The Company has issued service, performance and market based restricted share units to employees and directors of the Company. Expense for restricted share awards is amortized on a straight-line basis over the awards' vesting period.
The following table summarizes the restricted share unit activity for the period:
		2013						2012
		Number of			Weighted			Number of			Weighted
		Units			Average Fair Value			Units			Average Fair Value
Unvested - beginning of year			786,900		$	8.78			51,500		$	7.07
Granted			79,300			13.65			786,900			8.78
Vested			(145,650	)		10.18			(51,500	)		7.07
Unvested - end of year			720,550		$	9.03			786,900		$	8.78
In May 2013, the Company granted 38,200 restricted share units to members of the board of directors which will vest one year from the grant date. The fair market value at the grant date determined by the quoted market price was $525,632, or $13.76 per share. In February 2013, the Company granted 26,100 performance based restricted share units to executives which vested on December 31, 2013. The fair market value at the grant date was $359,136, or $13.76 per share.
Also during 2013, the Company granted 10,000 service-based restricted share units to a new board member vesting 25% each year beginning one year from grant date and 5,000 restricted share units to a former member of the board for past services, which were immediately vested. The aggregate fair market value at the grant date determined by the quoted market price of these awards was $198,000.
In December 2012, the Company granted 330,000 service-based restricted share units to employees and members of the board of directors which will vest 25% annually over a four year period from the grant date. The fair market value at the grant date determined by the quoted market price was $3,544,200, or $10.74 per share. Also in December 2012, the Company granted 405,000 market-based restricted share units to employees which will vest three years from the grant date based on the achievement of certain market conditions. The fair market value at the grant date determined by the binomial/lattice pricing model was $2,904,700, or $7.17 per share.
Also during 2012, the Company granted 27,900 performance-based restricted share units to employees vesting one year from grant date and 24,000 service based restricted share units to members of the board of directors vesting one year from grant date. The aggregate fair market value at the grant date determined by the quoted market price of these awards was $459,205.
In connection with the vesting of restricted share unit awards during the year ended Decmeber 31, 2013, 24,693 common stock shares with a fair value of $228,149 were withheld in satisfaction of employee tax withholding obligations. In connection with the vesting of restricted share unit awards during the year ended December 31, 2012, 8,419 common stock shares with a fair value of $80,550 were withheld in satisfaction of employee minimum tax withholding obligations.
During 2013 and 2012, restricted share unit compensation expense was $2,634,340 and $490,870, respectively, and included in selling, general and administrative expense.
As of December 31, 2013, the intrinsic value of the non-vested awards was $7,796,351 and there was $4,702,124 of unrecognized compensation cost related to unvested restricted share unit awards. These costs are expected to be recognized over the restricted shares units' remaining weighted average vesting period of 2.11 years.
During 2013, in consideration of prior service to the Company, a retiring director received 5,000 restricted share units, accelerated vesting of any unvested stock options and restricted share units and extended the date to exercise vested stock options to the earlier of 36 months or the awards original expiration date (versus 90 days) from the date of the retirement. Also, during 2013, the Company granted 4,450 shares of common stock to a former director for consulting services. An additional $337,422 of stock based compensation expense was recognized during 2013 and included in selling, general and administrative expense in connection with these activities. During 2012, in consideration of prior service to the Company, a retiring director received 2,500 shares of common stock, acceleration of vesting of any unvested restricted share units and extension of the date to exercise vested stock options to 36 months (versus 90 days) as of that date. Included in stock based compensation is a charge of $137,393 in connection with these benefits.
Shares Reserved for Future Issuance
At December 31, 2013, the Company had reserved the following shares of common stock for future issuance:
Convertible preferred shares (Series A - B)			73,332
Additional stock issuable related to conversion of
preferred stock			49,154
Common stock options outstanding			1,814,233
Common stock warrants outstanding			2,305,272
Restricted share units outstanding			720,550
Common stock equivalents available for grant			1,394,480
Total common stock shares reserved			6,357,021

Operating_Segments

Operating Segments	12 Months Ended
	Dec. 31, 2013
Operating Segments [Abstract]	'
Operating Segments	'
	11	Operating Segments
	The Company operates in three segments: advanced wound care, traditional wound care and pharmaceutical wound care products. They are managed separately as each segment requires different technology, marketing and sales strategies. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, bandages and ointments designed to promote wound healing and/or prevent infection. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closer strips, catheter fasteners and skin care products. Pharmaceutical wound care products consist of DSC127, a novel product for the treatment of a variety of dermal applications.
	Advanced and traditional wound care products are marketed globally to acute care, extended care, home health care, wound and burn care clinics and physician offices. The Company utilizes a broad network of well-established distributors to deploy the majority of its products to end users. A smaller portion of the Company's sales are sold directly to care providers and through retail. The advanced and traditional wound care products are both manufactured internally and sourced from third party suppliers. The majority of marketing expenses are deployed in support of advanced wound care products with traditional wound care products requiring limited support. The Company utilizes direct sales representatives, distributor relationships and contractual relationships with buying groups and wound care service providers to sell its products. Direct sales representatives are used solely in support of advanced wound care sales in the U.S. and the U.K. and for both advanced and traditional wound care products in Canada.
	The pharmaceutical wound care segment is presently limited to the development of DSC127 for diabetic foot ulcers and pre-clinical work on scar prevention.
	Each operating segment is managed at the segment contribution level consisting of gross profit minus direct expense consisting of distribution, marketing, sales, research and development and intangible amortization expenses. Expenses are allocated directly by segment to the extent possible. Expenses common to all three operating segments are allocated consistently using activity based assumptions. The aggregation or allocation of indirect expenses by segment is not practical.
	Operating segment sales, gross profit, segment contribution and other related information for 2013 and 2012 are as follows:
	Year Ended December 31, 2013
			Advanced Wound Care			Traditional   Wound Care			Pharmaceutical Wound Care			Other			Total
															Company
	Net sales		$	33,928,535		$	45,782,445		$	-		$	-		$	79,710,980
	Gross profit			16,837,797			12,552,677			-			-			29,390,474
	Direct expense			(21,404,045	)		(5,059,141	)		(11,434,557	)		-			(37,897,743	)
	Segment contribution		$	(4,566,248	)	$	7,493,536		$	(11,434,557	)		-			(8,507,269	)
	Indirect expenses											$	(15,456,784	)		(15,456,784	)
	Net loss														$	(23,964,053	)
	Depreciation		$	477,118		$	264,841		$	-		$	136,192		$	878,151
	Amortization		$	2,557,805		$	285,080		$	-		$	-		$	2,842,885
	As of December 31, 2013
	Equipment and improvements, net		$	2,188,389		$	562,480		$	-		$	202,600		$	2,953,469
	Identifiable intangible assets, net		$	13,614,210		$	1,021,788		$	-		$	-		$	14,635,998
	Goodwill		$	6,337,967		$	7,119,726		$	-		$	-		$	13,457,693
	Year Ended December 31, 2012
			Advanced Wound Care			Traditional   Wound Care			Pharmaceutical Wound Care			Other			Total
															Company
	Net sales		$	24,832,722		$	47,815,476		$	-		$	-		$	72,648,198
	Gross profit			12,458,920			12,681,929			-			-			25,140,849
	Direct expense			(17,658,759	)		(4,246,714	)		(7,177,823	)		-			(29,083,296	)
	Segment contribution		$	(5,199,839	)	$	8,435,215		$	(7,177,823	)		-			(3,942,447	)
	Indirect expenses											$	(8,127,984	)		(8,127,984	)
	Net loss														$	(12,070,431	)
	Depreciation		$	629,466		$	246,780		$	-		$	145,156		$	1,021,402
	Amortization		$	1,950,161		$	324,000		$	-		$	-		$	2,274,161
	As of December 31, 2012
	Equipment and improvements, net		$	2,194,498		$	708,653		$	-		$	401,701		$	3,304,852
	Identifiable intangible assets, net		$	15,822,016		$	1,306,867		$	-		$	-		$	17,128,883
	Goodwill		$	6,337,967		$	7,119,726		$	-		$	-		$	13,457,693
	A geographical breakdown of the Company's sales, gross profit and equipment and improvements, net are as follows:
			United States			Canada			Other			Total
	2013
	Net sales		$	61,234,755		$	11,084,430		$	7,391,795		$	79,710,980
	Gross profit		$	23,956,554		$	2,371,054		$	3,062,866		$	29,390,474
	Equipment and improvements,		$	459,859		$	2,258,544		$	235,066		$	2,953,469
	net
	2012
	Net sales		$	51,325,289		$	14,758,829		$	6,564,080		$	72,648,198
	Gross profit		$	18,609,115		$	3,747,557		$	2,784,177		$	25,140,849
	Equipment and improvements,		$	390,925		$	2,610,462		$	303,465		$	3,304,852
	net

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Income Taxes	'
		12	Income Taxes
	Loss before income taxes for the year ended December 31, 2013 and 2012 consist of the following components:
			2013			2012
	Domestic		$	(23,145,554	)	$	(14,590,416	)
	Foreign			(658,388	)		149,503
	Loss before income taxes		$	(23,803,942	)	$	(14,440,913	)
	The components of income taxes (benefit) for the year ended December 31 are as follows:
			2013			2012
	Current:
	Federal		$	-		$	-
	State			5,365			-
	Foreign			22,590			136,873
	Total current			27,955			136,873
	Deferred:
	Federal			149,108			(2,291,057	)
	State			(34,143	)		(219,463	)
	Foreign			17,191			3,165
	Total deferred			132,156			(2,507,355	)
	Total income taxes		$	160,111		$	(2,370,482	)
	In 2013, the Company recognized a $160,111 income tax expense consisting of a $120,330 U.S. income tax expense and a foreign income tax expense of $39,781. The U.S. income tax expense consists of a current tax expense of $5,365 and a deferred tax expense of $114,965. The deferred tax expense is due to differences in financial reporting and tax treatment of goodwill of $153,619 net of amortization for financial reporting but not tax purposes of acquired MedEfficiency identified intangible assets of $38,654.
	The reconciliation of income tax computed at the U.S. federal statutory tax rates to income tax expense along with percentage of loss before income taxes for the year ended December 31, 2013 and 2012 is as follows:
			2013						2012
	Tax benefit at federal statutory rate		$	(8,093,340	)		34	%	$	(4,909,912	)	34	%
	State tax, net of federal benefit			(750,351	)		3.2			(578,855	)	4
	Foreign tax			74,612			(0.3	)		-		-
	Nondeductible expenses			637,797			(2.7	)		781,791		(5.4	)
	Other			(50,860	)		0.2			(220,266	)	1.5
	Change in valuation allowance			8,342,253			(35.1	)		2,556,760		(17.7	)
	Income taxes		$	160,111			(0.7	%)	$	(2,370,482	)	16.4	%
	Significant components of the Company's deferred tax assets and liabilities are as follows:
			December 31,
			2013			2012
	Deferred tax assets:
	Net operating loss carryforwards		$	17,327,134		$	10,077,826
	Equity based compensation			1,281,192			798,701
	Allowance for sales deductions			165,142			182,002
	Amortization of identified intangibles			1,698,913			1,698,492
	Inventory adjustments			619,189			689,307
	Other			776,549			502,479
	Deferred tax assets			21,868,119			13,948,807
	Deferred tax liabilities:
	Prepaid expenses			(152,489	)		(135,914	)
	Goodwill			(1,181,379	)		(1,027,760	)
	Depreciation			(299,541	)		(192,438	)
	Indentified Intangibles			(2,780,224	)		(3,365,512	)
	Other			(654	)		(552	)
	Deferred tax liabilities			(4,414,287	)		(4,722,176	)
	Valuation allowance			(19,119,723	)		(10,777,470	)
	Net deferred tax liabilities		$	(1,665,891	)	$	(1,550,839	)
	The net deferred tax liability of $1,665,891 consists of a net noncurrent deferred tax liability of $1,694,147 and a net current deferred tax asset of $28,256 as of December 31, 2013. The net deferred tax liability includes a U.S. deferred tax liability of $1,181,379 related to differences in the basis for financial reporting and tax purposes for goodwill, a deferred liability of $225,309 related to intangible assets acquired from MedEfficiency and a $259,203 net deferred tax liability related to the Company's Canadian operations. The deferred tax asset is included in prepaid expenses and other current assets in the Consolidated Balance Sheet.
	At December 31, 2013, the Company has U.S. federal net operating loss carry forwards of approximately $46,343,000 that begin to expire in 2018. For U.S. state income tax purposes, the Company has net operating loss carry forwards in a number of jurisdictions in varying amounts and with varying expiration dates. Federal and state net operating loss carryforwards include excess stock-based compensation benefit deductions of which, if recognized in the future, will be recorded as additional paid in capital in the Consolidated Balance Sheet. The Company also has $1,015,000 in research and development tax credit carry forwards and $179,000 in foreign tax credit carry forwards which begin to expire in 2031and 2019, respectively.
	The Company has determined that the amount by which the U.S. federal net operating loss carryforwards can be utilized in any year is limited under the Internal Revenue Code Section 382 regarding changes in ownership of corporations. Due to uncertainties surrounding the Company's ability to use its net operating loss carryforwards, foreign tax credit and realize the other net deferred tax assets based on historical operating results and ownership change limitations a full valuation allowance has been provided as of December 31, 2013 and 2012 for the deferred tax assets for the U.S. and U.K.

Retirement_Benefits

Retirement Benefits	12 Months Ended
	Dec. 31, 2013
Retirement Benefits [Abstract]	'
Retirement Benefits	'
	13	Retirement Benefits
	The Company maintains a profit sharing 401(k) plan for eligible full-time U.S. employees. Participants may contribute a fixed percentage of their salary to the plan, subject to IRS limitations. The Company makes a matching contribution up to a maximum amount of each participant's annual base salary earnings contributed to the plan. During 2013 and 2012, the Company matched 100% on the first 4% of each participant's contributed annual base salary. Company contributions to the plan for the years ended December 31, 2013 and 2012 were $303,913 and $208,654, respectively.
	The Company's Canadian subsidiary maintains a group retirement savings plan (Registered Retirement Savings Plan) for eligible full time Canadian employees. The Canadian subsidiary makes a matching contribution to the plan based on a percentage of each participant's contributed annual gross earnings. Employee contribution limits to the group retirement savings plan are set by the Canada Customs and Revenue Agency. During 2013 and 2012, the Company matched 100% on the first 4% of each participant's contributed annual gross earnings. The Company's Canadian subsidiary's contributions to the plan for the year ended December 31, 2013 and 2012 were $133,319 and $109,442, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
		14	Commitments and Contingencies
	Operating Leases
	The Company has non-cancelable operating lease agreements for its facilities and equipment expiring in various years through 2019. Total lease expense under these lease agreements was $1,227,718 and $1,544,575 in 2013 and 2012, respectively. Total minimum lease payments under each lease are recorded on a straight-line basis to lease expense over the lease term. Differences between the recognition of lease expense on a straight-line basis and payments owed and/or free rent are recorded as deferred rent. Tenant improvement allowances are recorded as deferred lease expense as received, and amortized to lease expense over the lesser of the corresponding asset life or the lease term. At December 31, 2013 and 2012, the Company had deferred rent of $242,325 and $268,517, respectively, recorded in long-term liabilities on the Consolidated Balance Sheet.
	The leases generally provide for scheduled increases in future minimum annual lease payments over the life of the lease and for renewal options consistent with the terms of the existing lease. It is expected that these leases will be renewed or replaced by leases on other property and equipment, as needed.
	Minimum future lease payments under existing operating leases as of December 31, 2013 are:
	Minimum Future Rental Payments
	Year Ending December 31,		Amount
	2014		$	1,289,799
	2015			1,043,225
	2016			940,565
	2017			804,561
	2018			490,598
	Thereafter			4,014
	Net minimum future rental payments		$	4,572,762
	Comvita Licensing Agreement
	In February 2010, the Company entered into a new agreement with Comvita under which the Company received perpetual and exclusive worldwide licensing rights for Manuka Honey based Medihoney wound and skin care products for all markets outside of the consumer market (the "Comvita Agreement"). The Comvita Agreement supersedes the prior agreement, which was terminated as of the effective date. The Comvita Agreement also provides that Comvita will serve as the Company's exclusive supplier for Manuka Honey and will not provide Manuka Honey to any other entities for use in the professional medical-surgical marketplace. The Comvita Agreement calls for graduated royalty payments based on sales and milestone payments of up to $20,000,000 based on achievement of specified net sales objectives of which $2,000,000 has been incurred and paid through December 31, 2013. The license rights may be terminated or rendered non-exclusive by Comvita if the Company fails to meet certain minimum royalty requirements.
	In October 2012, the Company met the criteria for payment of the second Medihoney milestone payment under the Comvita Agreement based on achieving Medihoney sales in excess of $10,000,000 for the trailing twelve month period. During the year, the $1,000,000 milestone payment was recorded as an addition to the Medihoney license intangible asset and is being amortized to cost of sales. Another milestone payment of $1,000,000 was made in a prior year.
	Comvita is a major stockholder of the Company and its Chief Executive Officer serves on the Company's Board of Directors. The Company purchased $2,266,964 and $1,653,075 of medical grade honey from Comvita in 2013 and 2012, respectively. In addition, the Company incurred Medihoney royalties of $1,240,818 and $901,826 in 2013 and 2012, respectively. Amounts due to Comvita for raw material purchases and royalties totaled $421,578 and $288,596 at December 31, 2013 and 2012, respectively. During 2013, the Company also purchased an equity investment in Comvita stock for $7,000,000 (note 4).
	Quick-Med Technologies, Inc. - License Agreement
	In July 2012, the Company entered into a new patent and technology license agreement (the "QMT Agreement") with Quick-Med Technologies, Inc. ("QMT") relating to QMT's proprietary anti-microbial technology (the "Technology") utilized in the Company's Bioguard products. The QMT Agreement supersedes a prior agreement, which had been in effect since March 2007.
	Under the QMT Agreement, QMT granted to the Company an exclusive, royalty-bearing right and license to make, use and sell products incorporating the Technology worldwide, except for India (the "Territory"). If the Company does not achieve the first commercial sale of a product incorporating the Technology in Europe and in Asia and Central and South America by certain dates, or in the event that, for a given calendar year, the Company fails to meet a minimum net sales requirement under the QMT Agreement, QMT has the right, as its sole remedy within each geographic area affected, to either terminate the QMT Agreement or convert the exclusive license in that geographic area to a non-exclusive license. Unless otherwise terminated pursuant to the QMT Agreement, the term of the QMT Agreement continues, with respect to each country in the Territory, until the expiration of the patent rights in that country.
	In 2012, the Company paid QMT an upfront license fee of $1,300,000. This upfront fee has been capitalized as an identifiable intangible asset and is being amortized over its estimated useful life of seven years. In addition to the upfront license fee, royalties are payable to QMT based upon a sliding scale of the Company's net sales of products incorporating the Technology and declining as net sales increase. The QMT Agreement also requires the Company to make certain milestone payments of up to $3,500,000 to QMT based upon the achievement of certain net sales levels for four consecutive calendar quarters. In 2013 and 2012, the Company incurred QMT royalties of $202,377 and $279,537, respectively.
	In the event that QMT desires to sell the Technology, patent rights and improvements or QMT receives a bona fide offer from an unaffiliated third party to purchase the same during the term of the QMT Agreement, the Company has the right of first negotiations or right of first refusal, respectively, relating to any such sale.
	USC License Agreement
	In November 2007, the Company entered into a license agreement (the "License Agreement") with the University of Southern California ("USC") pursuant to which the Company acquired exclusive rights to a number of U.S. and foreign patents and non-exclusive rights to one patent, together with trade secrets and know-how, related to an angiotensin analog (the patents, trade secrets and know-how, collectively, the "Angiotensin Analog Technology"). The Angiotensin Analog Technology relates to all dermal applications including applications for the treatment of chronic wounds such as diabetic ulcers, leg ulcers associated with venous insufficiency, pressure ulcers (bed sores), burns and surgical scars.
	The Company paid to or on behalf of USC an initial license fee which was charged to expense. The Company will pay USC royalties relative to sales of products employing the Angiotensin Analog Technology (the "Angiotensin Products") at specified rates in respect of revenues less than $100 million and revenues equal to or greater than $100 million, respectively, together with milestone payments of up to $9,625,000 predicated upon obtaining FDA approval of the various indications for the Angiotensin Products, as well as the attainment of various sales objectives.
	The compound employing the Angiotensin Analog Technology is classified as a "drug," the sale of which is conditioned upon FDA approval. The process of obtaining FDA approval for the compound consists of subjecting the compound to a series of pre-clinical and clinical studies, these latter known as Phase 1, Phase 2 and Phase 3 studies.
	Our first product, DSC 127, utilizing this compound for the treatment of diabetic foot ulcers has successfully undergone pre-clinical, Phase 1 and Phase 2 clinical studies for use in the treatment of diabetic foot ulcers. The first of two Phase 3 clinical trials commenced in the first quarter of 2013, with the second commencing during the second quarter of 2013.
	The Company is under no obligation to undertake or complete further studies in respect of the Angiotensin Analog Technology. Should it not do so, the Company may either sublicense the Angiotensin Analog Technology to one or more third parties or release the Angiotensin Analog Technology to USC. In this latter event, USC would reimburse the Company for certain of its costs incident to clinical studies that have heretofore been performed.
	Canadian Distribution Agreement
	In May 2005, the Company entered into a distribution agreement with a Canadian company to serve as the exclusive distributor of its products in Canada. The agreement also appoints the distributor as the Company's servicing agent to fulfill supply contracts held directly by the Company. The agreement was most recently amended in January 2011, extending it through April 2016. The Company recognizes revenue under the agreement when title and risk of loss pass to the distributor and collectability is reasonably assured, which is at the time product is shipped to the distributor. Payment terms from the distributor are 30 days. Either party has the right to terminate the agreement when an event of default (as defined) has occurred with respect to the other party. The distributor is entitled to continue to sell or otherwise dispose of all inventory owned by it from and after the date of contract expiration or termination. If termination of the agreement is not occasioned by breach by the distributor, the distributor will be entitled on notice to the Company to return saleable inventory (as defined) to the Company. Estimated returns are reserved at the time of sale. Since the inception of the agreement, sales returns have been minimal.
	The distributor assumes responsibility for customer service, product delivery and maintenance and warehousing of sufficient inventory to meet agreed upon order fulfillment requirements. On an ongoing basis, the distributor places inventory replenishment orders with the Company at agreed upon prices, 120 days in advance of scheduled delivery. Unless amended, each order becomes non-cancelable 90 days in advance of scheduled delivery.
	With respect to sales made by the distributor, the Company pays the distributor an agreed upon distribution fee. The Company reimburses the distributor for the difference between the price paid by the distributor and the Company's contract price with the end customer, upon submission by the distributor of an agreed upon rebate report. The distribution fee is recorded as a reduction of revenue under this agreement.
	Executive Employment Agreements
	The five executive officers of the Company are appointed by and serve at the discretion of the Board of Directors pursuant to one year employment agreements that are subject to renewal annually as of April 1st. The agreements were renewed in March 2013. The agreements provide for annual salary and provision for bonus and equity based compensation assuming financial and personal objectives are met. The agreements also outline certain obligations that may be triggered by a change in control and severance for failure to renew an agreement other than for cause.
	New Cast Industry Co., Ltd. Supply Agreement
	On March 27, 2013, the Company entered into a supply agreement (the "International Agreement") with New Cast Industry Co., Ltd. ("NCIC") relating to NCIC's proprietary technology for the casting element within the TCC-EZ total contact casting system (the "Technology"). The Company has been purchasing product from NCIC utilizing the Technology in the TCC-EZ series of total contact casting system products for TCC-EZ product sales within North America pursuant to the supply agreement dated April 17, 2012 (the "North America Agreement"), and intends to continue to do so.
	Under the International Agreement, NCIC agreed to exclusively supply the Company with its product utilizing the Technology and granted the Company the exclusive right to sell products incorporating the Technology outside North America. If the Company does not achieve the first commercial sale of a product incorporating the Technology in Latin America, Europe, Middle East, Australia, Asia and India (the "Territory") by certain dates, NCIC has the right, as its sole remedy, to convert the exclusive license in the Territory to a non-exclusive license. Unless otherwise terminated pursuant to the terms of the International Agreement, the term is for five years with automatic five year renewals.
	In consideration for the exclusive international rights set forth above, the Company paid NCIC $200,000. Provided this agreement has not been terminated as a result of a breach by the Company, NCIC will refund $100,000 to the Company on the first anniversary of the International Agreement. The initial cost of $100,000 has been capitalized as an identifiable intangible asset and is being amortized over the initial five year term of the agreement, and a $100,000 deposit has been recorded. Further, the International Agreement includes milestone payments of up to $1,000,000 to NCIC based upon achievement of international net sales levels during a calendar year.
	Contingencies
	On occasion, the Company is involved in claims and other legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on the Company's consolidated financial position, results of operations, or liquidity.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	15	Subsequent Events
	BioDLogics, LLC License Agreement
	On January 14, 2014, the Company entered into a license, market development and commercialization agreement (the "Agreement") with BioDLogics, LLC ("BioD") relating to BioD's human placental based products (the "Licensed Products") and intellectual property related thereto.
	Under the Agreement, BioD granted to the Company an exclusive, perpetual, royalty-bearing license to use, offer for sale and sell, the Licensed Products in North America (the "Territory"), including the rights to sublicense solely as provided in the Agreement, for a broad range of dermal applications, (the "Field"). During the term of the Agreement, the Company must use diligent efforts, and will be responsible for the sale and marketing of the Licensed Products in the Field throughout the Territory. As part of its commercialization efforts, the Company will fund clinical studies in support of the Field pursuant to the Agreement.
	The Company agreed to pay to BioD an initial license fee of $1,250,000 and granted BioD a warrant to purchase 100,000 shares of the Company's common stock. One quarter (25%) of the warrant is exerciseable immediately at a price of $11.81, while the remaining 75% of the warrant becomes exercisable, if at all, upon the achievement of certain milestones. The warrant expires five years from the date of issuance in January 2019. In addition to the initial license fee and warrant, royalties are payable to BioD based upon a sliding scale of the Company's net sales of Licensed Products within the Territory and declining as net sales increase. The Agreement also requires the Company to make milestone payments to BioD of up to $19,750,000 based upon the achievement of certain development events and annual net sales levels.
	The Agreement may be terminated as follows: (i) upon mutual agreement of the parties; (ii) by BioD if the Company challenges certain BioD patents or trade secrets; (iii) by BioD if the Company fails to meet the annual minimum net sales requirement under the Agreement, unless the Company pays the difference between the amount of royalties that would have been due had the minimum annual net sales for such year been achieved and royalty payments made by the Company with respect to net sales during such year plus any milestone payments payable; or (iv) by either party in the event of a material breach or certain events of bankruptcy.
	Equity Offering
	On January 29, 2014, the Company raised $80,675,000 (net of $5,575,000 in estimated commission and other offering expenses) from the sale of 7,500,000 shares of the Company's common stock at $11.50 per share. The Company plans to use the net proceeds from the offering for the continued development of its pharmaceutical product DSC127, for sales force expansion and for general corporate purposes.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation - The consolidated financial statements include the accounts of Derma Sciences, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates - The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although these estimates are based on knowledge of current events and actions which may be undertaken in the future, actual results may ultimately differ from these estimates. Estimates and assumptions are required in the determination of sales deductions for trade rebates, sales incentives, discounts and allowances. Significant estimates and assumptions are also required in determining the appropriateness of amortization periods for identifiable intangible assets, the potential impairment of goodwill and the valuation of inventory.
Foreign Currency Translation	'
	Foreign Currency Translation - Assets and liabilities are translated using the exchange rates in effect at the balance sheet date, while income and expenses are translated using average rates during the period. Translation adjustments are reported as a component of stockholders' equity in accumulated other comprehensive income. For the Company's foreign subsidiaries, exchange rate fluctuations on foreign currency denominated assets and liabilities other than the functional currency resulted in income of $140,721 and $47,738 for the years ended December 31, 2013 and 2012, respectively, which is included in the Consolidated Statement of Comprehensive Loss as follows:
		2013			2012
	Cost of sales	$	57,894		$	7,031
	Other income, net		(198,615	)		(54,769	)
	Total	$	(140,721	)	$	(47,738	)
	Exchange rate fluctuations of foreign currency denominated assets and liabilities associated with inventory are included in cost of sales, while all other such fluctuations are included in other income, net.
Concentration of Credit Risk	'
	Concentration of Credit Risk - Financial instruments that subject the Company to a concentration of credit risk consist principally of cash and cash equivalents, investments in debt securities and accounts receivable. The Company maintains cash and cash equivalents with various financial institutions in amounts which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts. The Company does not require collateral or other security to support credit sales, but provides an allowance for doubtful accounts based on historical experience and specifically identified risks. Accounts receivable are charged off against the allowance for doubtful accounts when management determines that recovery is unlikely and the Company ceases collection efforts.
Inventories	'
	Inventories - Inventories consist of raw materials, packaging materials, work in process and finished goods valued at the lower of cost or market. Cost is determined on the basis of the first-in, first-out method.
Equipment and improvements	'
	Equipment and improvements - Equipment and improvements are stated at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets ranging from three to 10 years. Leasehold improvements are amortized over the lesser of their useful lives or the remaining lease term.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments - The carrying value of cash equivalents, accounts receivable, prepaid expenses and other current assets, and accounts payable reported in the consolidated balance sheets equal or approximate fair value due to their short term nature.
Identifiable Intangible Assets	'
	Identifiable Intangible Assets - Identifiable intangible assets, which consist of product license rights, developed technology and supply agreements, and other identifiable intangible assets, are amortized over one to 13 years on a straight-line basis.
Long-Lived Assets	'
	Long Lived Assets -The Company reviews its long-lived assets with definitive lives whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If the carrying amount of the asset or group of assets exceeds its net realizable value, the asset will be written down to its fair value.
Goodwill	'
	Goodwill - The Company tests goodwill for impairment using a two-step process. The first step tests for potential impairment, while the second step measures the amount of impairment, if any. The Company uses a discounted cash flow analysis to complete the first step in this process. If the first step indicates an impairment, i.e. when the carrying value exceeds the fair value, then the second step is required to determine the implied fair value of goodwill. The implied fair value of goodwill is calculated in the same manner that goodwill is calculated in a business combination. The allocation is to be performed as if the reporting unit had just been acquired and the fair value of the unit was the purchase price. The goodwill impairment equals the carrying value of goodwill less the implied fair value of goodwill. The Company performs its goodwill impairment test as of December 31st of each year, or more frequently if impairment indicators are present.
Stock-Based Compensation	'
	Stock-Based Compensation - Stock-based compensation for share-based awards with employees and non-employee directors, such as grants of stock options and restricted share units, are recognized in the consolidated financial statements based on the fair value of the award at the grant date on a straight-line basis over the requisite service or performance periods. Stock-based compensation for share-based awards granted to consultants are recognized based on the fair value of the award on a straight-line basis over the requisite service or performance periods and are revalued at the end of each period until the award vests. The Company estimates the fair value of stock options using the Black-Scholes option-pricing model for service and performance based awards. The fair value of restricted share units is based on the quoted market price for service and performance based awards, and by using a binomial/lattice pricing model for market based awards. The Company issues new common stock shares upon exercise of share-based awards.
Income Taxes	'
	Income Taxes - Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets, including tax loss and credit carryforwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The effect of income tax positions is recognized only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.
	The Company measures and recognizes the tax implications of positions taken or expected to be taken in its tax returns on an ongoing basis. In 2013 and 2012, the Company had no unrecognized tax benefits or liabilities, and no adjustment to its financial position, results of operations or cash flows were required. The Company records interest and penalties related to tax matters within other income, net on the accompanying Consolidated Statements of Comprehensive Loss. These amounts are not material to the consolidated financial statements for the periods presented. The Company's U.S. tax returns are subject to examination by federal and state taxing authorities. Tax years prior to 2010 are no longer subject to federal examination. However, the Company's federal net operating losses for tax years 1999 through 2009 will remain subject to examination until the losses are utilized or expire. State tax years 2009 to 2013 remain open to examination by the various state jurisdictions in which the Company is subject to tax. Tax years prior to 2005 are no longer subject to examination in Canada. The U.K. tax returns since the inception of the subsidiary in 2010 are subject to examination.
Revenue Recognition	'
	Revenue Recognition - Sales are recorded when product is shipped or title passes to customers and collectability is reasonably assured. Gross sales are adjusted for cash discounts, returns and allowances, trade rebates, distribution fees (in Canada) and other sales deductions in the same period that the related sales are recorded. Freight costs billed to and reimbursed by customers are recorded as a component of revenue. Freight costs to ship product to customers are recorded as a component of cost of sales.
Advertising and Promotion Costs	'
	Advertising and Promotion Costs - Advertising and promotion costs are charged to expense as incurred and were $3,082,221 and $2,243,387 in 2013 and 2012, respectively.
Royalties	'
	Royalties - The Company recognizes royalty expenses associated with the products sold at the time the related sale occurs and records them as a component of cost of sales. Royalty expense for the years ended December 31, 2013 and 2012 was $1,741,742 and $1,395,567, respectively.
Net Loss per Share	'
	Net Loss per Share - Net loss per common share - basic is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Net loss per common share - diluted reflects the potential dilution of earnings by including the effects of the assumed exercise, conversion or issuance of potentially issuable shares of common stock ("potentially dilutive securities"), including those attributable to stock options, warrants, convertible preferred stock and restricted share units in the weighted average number of common shares outstanding for a period, if dilutive. The effects of the assumed exercise of warrants and stock options are determined using the treasury stock method. Potentially dilutive securities have not been included in the computation of diluted loss per share for the years ended December 31, 2013 and 2012 as the effect would be anti-dilutive.
	Potentially dilutive shares excluded as a result of the effects being anti-dilutive are as follows:
		Year Ended December 31,
		2013			2012
	Excluded dilutive shares:
	Convertible preferred stock		73,332			73,332
	Additional stock issuable related
	to conversion of preferred stock		49,154			-
	Restricted share units		720,550			786,900
	Stock options		1,814,233			1,639,985
	Warrants		2,305,272			2,930,154
	Total dilutive shares		4,962,541			5,430,371
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements - In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, which requires companies to present information about reclassifications out of accumulated other comprehensive income in a single note or on the face of the financial statements. The updated standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2012, with early adoption permitted. The adoption of this standard did not have a material impact on the Company's consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Description of Business [Abstract]	'
Schedule of Foreign Currency Income	'
		2013			2012
	Cost of sales	$	57,894		$	7,031
	Other income, net		(198,615	)		(54,769	)
	Total	$	(140,721	)	$	(47,738	)
Potentially Dilutive Shares Excluded as Result of Effects Being Anti-dilutive	'
		Year Ended December 31,
		2013			2012
	Excluded dilutive shares:
	Convertible preferred stock		73,332			73,332
	Additional stock issuable related
	to conversion of preferred stock		49,154			-
	Restricted share units		720,550			786,900
	Stock options		1,814,233			1,639,985
	Warrants		2,305,272			2,930,154
	Total dilutive shares		4,962,541			5,430,371

Acquisition_Tables

Acquisition (Tables)	12 Months Ended
	Dec. 31, 2013
Acquisition [Abstract]	'
Allocation of Purchase Price of Assets Acquired and Liabilities Assumed	'
	Current assets	$	925,817
	Equipment		29,579
	Acquired intangible assets		10,700,000
	Goodwill		6,337,967
	Total assets acquired		17,993,363
	Current liabilities		653,315
	Deferred tax liability		2,982,470
	Total liabilities assumed		3,635,785
	Net assets acquired	$	14,357,578
	Purchase price	$	14,475,000
	Less cash acquired		117,422
	Net cash paid	$	14,357,578
Combined Results of Operations as if Acquisition Had Occurred at Beginning of Period	'
		Year ended,
		31-Dec-12
		(Unaudited)
	Net Sales	$	74,035,688
	Net Loss	$	(12,762,551	)
	Net Loss per common share -
	basic and diluted	$	(1.02	)
	Weighted average number of shares -
	basic and diluted		12,488,263

Cash_and_Cash_Equivalents_and_1

Cash and Cash Equivalents and Investments (Tables)	12 Months Ended
	Dec. 31, 2013
Cash and Cash Equivalents and Investments [Abstract]	'
Schedule of Cash and Cash Equivalents and Investments	'
		December 31,
		2013		2012
	Cash	$	5,265,903	$	4,909,663
	Money market mutual funds		1,235,683		36,706,994
	Cash and cash equivalents		6,501,586		41,616,657
	Investments in debt securities		16,474,000		4,228,000
	Investment in equity securities		6,862,140		-
	Total investments		23,336,140		4,228,000
	Total cash and cash equivalents and investments	$	29,837,726	$	45,844,657
Fair Value of Cash and Cash Equivalents and Investments	'
	The following table provides fair value information as of December 31, 2013:
				Fair Value Measurements, Using
		Total carrying		Quoted prices		Significant other		Significant
		value as of		in active		observable		unobservable
		31-Dec-13		markets		inputs		inputs
				(Level 1)		(Level 2)		(Level 3)
	Cash and cash equivalents	$	6,501,586	$	6,501,586	$	-	$	-
	Investments in debt securities		16,474,000		16,463,473		-		-
	Investment in equity securities		6,862,140		6,862,140		-		-
	Total Investments		23,336,140		23,325,613		-		-
	Total	$	29,837,726	$	29,827,199	$	-	$	-
	The following table provides fair value information as of December 31, 2012:
				Fair Value Measurements, Using
		Total carrying		Quoted prices		Significant other		Significant
		value as of		in active		observable		unobservable
		31-Dec-12		markets		inputs		inputs
				(Level 1)		(Level 2)		(Level 3)
	Cash and cash equivalents	$	41,616,657	$	41,616,657	$	-	$	-
	Investments in debt securities		4,228,000		4,216,156		-		-
	Total	$	45,844,657	$	45,832,813	$	-	$	-

Accounts_Receivable_net_Tables

Accounts Receivable, net (Tables)	12 Months Ended
	Dec. 31, 2013
Accounts Receivable, net [Abstract]	'
Schedule of Accounts Receivable	'
		December 31,
		2013			2012
	Accounts receivable	$	7,781,482		$	7,557,862
	Less: Allowance for doubtful accounts		(97,729	)		(147,843	)
	Allowance for trade rebates		(218,700	)		(197,650	)
	Allowance for cash discounts and returns		(132,297	)		(126,656	)
	Accounts receivable, net	$	7,332,756		$	7,085,713

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventories [Abstract]	'
Schedule of Inventories	'
		December 31,
		2013		2012
	Finished goods	$	11,044,746	$	9,574,685
	Work in process		1,009,315		554,129
	Packaging materials		1,408,521		991,157
	Raw materials		3,010,058		2,550,617
	Total inventory	$	16,472,640	$	13,670,588

Equipment_and_Improvements_net1

Equipment and Improvements, net (Tables)	12 Months Ended
	Dec. 31, 2013
Equipment and Improvements, net [Abstract]	'
Schedule of Equipment and Improvements	'
		December 31,
		2013			2012
	Machinery and equipment	$	7,102,144		$	7,135,714
	Furniture and fixtures		911,879			843,149
	Leasehold improvements		2,300,500			2,226,022
			10,314,523			10,204,885
	Less: accumulated depreciation		(7,361,054	)		(6,900,033	)
	Total equipment and improvements, net	$	2,953,469		$	3,304,852

Identifiable_Intangible_Assets1

Identifiable Intangible Assets, net (Tables)	12 Months Ended
	Dec. 31, 2013
Identifiable Intangible Assets, net [Abstract]	'
Schedule of Identifiable Intangible Assets	'
		December 31,						Amortization Period
		2013			2012
	Product license rights	$	8,217,126		$	7,967,126		6-10 years
	Developed technology and supply agreements		7,700,000			7,600,000		5-7 years
	Other		6,400,000			6,400,000		1-10 years
			22,317,126			21,967,126
	Less accumulated amortization		(7,681,128	)		(4,838,243	)
	Total identifiable intangible assets, net	$	14,635,998		$	17,128,883
Schedule of Amortization Expense	'
		2013			2012
	Cost of sales	$	2,009,472		$	1,461,411
	Selling, general and administrative expenses		833,413			812,750
	Total amortization expense	$	2,842,885		$	2,274,161
Schedule of Estimated Future Amortization Expense	'
		Product License Rights			Developed			Other		Total
					Technology and Supply Agreements
	Amortization expense for	$	908,758		$	1,100,714		$	833,413	$	2,842,885
	year ended December 31, 2013
	Weighted Average Useful Life		6			5.3			3.2		4.8
	Amortization expense for	$	692,363		$	769,048		$	812,750	$	2,274,161
	year ended December 31, 2012
	Estimated amortization expense for years ending December 31,
	2014	$	946,613		$	1,105,715		$	775,000	$	2,827,328
	2015		946,613			1,105,715			775,000		2,827,328
	2016		946,613			1,105,715			626,250		2,678,578
	2017		946,613			1,105,715			281,667		2,333,995
	2018		946,613			1,025,295			165,000		2,136,908
	Thereafter		987,990			382,083			461,788		1,831,861
		$	5,721,055		$	5,830,238		$	3,084,705	$	14,635,998

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Accrued Expenses and Other Current Liabilities [Abstract]	'
Schedule of Accrued Expenses and Other Current Liabilities	'
		December 31,
		2013		2012
	Accrued compensation and related taxes	$	2,529,211	$	1,929,524
	Accrued Canadian sales rebate, net (note 14)		252,671		636,633
	Accrued royalties		361,559		427,075
	Accrued sales incentives and other fees		546,296		316,209
	Other		1,279,488		823,493
	Total accrued expenses and other current liabilities	$	4,969,225	$	4,132,934

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity [Abstract]	'
Schedule of Warrants Outstanding	'
	Series	Number of Warrants			Exercise Price			Expiration Date
	L		6,250		$	3.12		31-Mar-14
	N		100,000		$	6.25		22-Feb-15
	O		230,900		$	5.5		22-Feb-15
	P		2,187		$	6.25		16-Feb-15
	Q		133,333		$	5.5		22-Feb-15
	R		1,832,602		$	9.9		22-Jun-16
	Total	$	2,305,272
Weighted Average Assumptions Used in Estimation of Fair Value of Option Awards	'
		2013			2012
	Risk-free interest rate		1.22	%		1.11	%
	Volatility factor		69.9	%		73.6	%
	Dividend yield		0	%		0	%
	Expected option life (years)		6.14			6.25
Summary of Stock Option Activity	'
		2013						2012
		Options			Weighted Average Exercise Price			Options			Weighted Average Exercise Price
	Outstanding - beginning of year		1,639,985		$	6.38			1,582,683		$	5.82
	Granted		421,480		$	12.14			268,160		$	8.93
	Forfeited		(36,878	)	$	10.99			(61,825	)	$	7.53
	Exercised		(184,824	)	$	5.5			(149,033	)	$	4.37
	Expired		(25,530	)	$	13.16			-			-
	Outstanding - end of year		1,814,233		$	7.67			1,639,985		$	6.38
	Expected to vest - end of year		1,796,091		$	7.67			1,623,585		$	6.38
	Exercisable at end of year		1,443,409		$	6.84			1,208,077		$	5.86
Schedule of Information about Stock Options Outstanding and Exercisable by Exercise Price Range	'
		Options Outstanding									Options Exercisable
	Range of	Number Outstanding			Weighted-Average Remaining Contractual Life			Weighted-Average Exercise Price			Number Exercisable		Weighted-Average Exercise Price
	Exercise Prices
	$2.88 - $4.00		251,961			3.38		$	3.43			251,961	$	3.43
	$4.01 - $6.00		473,412			5.18		$	5.13			463,912	$	5.13
	$6.01 - $10.00		610,470			6.77		$	8.03			500,799	$	7.95
	$10.01 - $13.99		478,390			8.59		$	11.97			226,737	$	11.66
			1,814,233			6.36		$	7.67			1,443,409	$	6.84
Allocation of Stock Option Compensation Expense	'
		2013			2012
	Cost of sales	$	95,726		$	39,789
	Selling, general and administrative expenses		2,087,827			1,470,269
	Research and development		165,581			103,289
	Total stock option compensation expense	$	2,349,134		$	1,613,347
Summary of Restricted Share Unit Activity	'
		2013						2012
		Number of			Weighted			Number of			Weighted
		Units			Average Fair Value			Units			Average Fair Value
	Unvested - beginning of year		786,900		$	8.78			51,500		$	7.07
	Granted		79,300			13.65			786,900			8.78
	Vested		(145,650	)		10.18			(51,500	)		7.07
	Unvested - end of year		720,550		$	9.03			786,900		$	8.78
Common Stock Shares Reserved for Future Issuance	'
	Convertible preferred shares (Series A - B)		73,332
	Additional stock issuable related to conversion of
	preferred stock		49,154
	Common stock options outstanding		1,814,233
	Common stock warrants outstanding		2,305,272
	Restricted share units outstanding		720,550
	Common stock equivalents available for grant		1,394,480
	Total common stock shares reserved		6,357,021

Operating_Segments_Tables

Operating Segments (Tables)	12 Months Ended
	Dec. 31, 2013
Operating Segments [Abstract]	'
Schedule of Operating Segment Sales, Gross Profit, Segment Contribution and Other Related Information	'
	Year Ended December 31, 2013
		Advanced Wound Care			Traditional   Wound Care			Pharmaceutical Wound Care			Other			Total
														Company
	Net sales	$	33,928,535		$	45,782,445		$	-		$	-		$	79,710,980
	Gross profit		16,837,797			12,552,677			-			-			29,390,474
	Direct expense		(21,404,045	)		(5,059,141	)		(11,434,557	)		-			(37,897,743	)
	Segment contribution	$	(4,566,248	)	$	7,493,536		$	(11,434,557	)		-			(8,507,269	)
	Indirect expenses										$	(15,456,784	)		(15,456,784	)
	Net loss													$	(23,964,053	)
	Depreciation	$	477,118		$	264,841		$	-		$	136,192		$	878,151
	Amortization	$	2,557,805		$	285,080		$	-		$	-		$	2,842,885
	As of December 31, 2013
	Equipment and improvements, net	$	2,188,389		$	562,480		$	-		$	202,600		$	2,953,469
	Identifiable intangible assets, net	$	13,614,210		$	1,021,788		$	-		$	-		$	14,635,998
	Goodwill	$	6,337,967		$	7,119,726		$	-		$	-		$	13,457,693
	Year Ended December 31, 2012
		Advanced Wound Care			Traditional   Wound Care			Pharmaceutical Wound Care			Other			Total
														Company
	Net sales	$	24,832,722		$	47,815,476		$	-		$	-		$	72,648,198
	Gross profit		12,458,920			12,681,929			-			-			25,140,849
	Direct expense		(17,658,759	)		(4,246,714	)		(7,177,823	)		-			(29,083,296	)
	Segment contribution	$	(5,199,839	)	$	8,435,215		$	(7,177,823	)		-			(3,942,447	)
	Indirect expenses										$	(8,127,984	)		(8,127,984	)
	Net loss													$	(12,070,431	)
	Depreciation	$	629,466		$	246,780		$	-		$	145,156		$	1,021,402
	Amortization	$	1,950,161		$	324,000		$	-		$	-		$	2,274,161
	As of December 31, 2012
	Equipment and improvements, net	$	2,194,498		$	708,653		$	-		$	401,701		$	3,304,852
	Identifiable intangible assets, net	$	15,822,016		$	1,306,867		$	-		$	-		$	17,128,883
	Goodwill	$	6,337,967		$	7,119,726		$	-		$	-		$	13,457,693
Schedule of Sales, Gross Profit and Net Equipment and Improvements	'
		United States			Canada			Other			Total
	2013
	Net sales	$	61,234,755		$	11,084,430		$	7,391,795		$	79,710,980
	Gross profit	$	23,956,554		$	2,371,054		$	3,062,866		$	29,390,474
	Equipment and improvements,	$	459,859		$	2,258,544		$	235,066		$	2,953,469
	net
	2012
	Net sales	$	51,325,289		$	14,758,829		$	6,564,080		$	72,648,198
	Gross profit	$	18,609,115		$	3,747,557		$	2,784,177		$	25,140,849
	Equipment and improvements,	$	390,925		$	2,610,462		$	303,465		$	3,304,852
	net

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes [Abstract]	'
Schedule of Loss before Income Taxes	'
		2013			2012
	Domestic	$	(23,145,554	)	$	(14,590,416	)
	Foreign		(658,388	)		149,503
	Loss before income taxes	$	(23,803,942	)	$	(14,440,913	)
Schedule of Income Tax Expense (Benefit)	'
		2013			2012
	Current:
	Federal	$	-		$	-
	State		5,365			-
	Foreign		22,590			136,873
	Total current		27,955			136,873
	Deferred:
	Federal		149,108			(2,291,057	)
	State		(34,143	)		(219,463	)
	Foreign		17,191			3,165
	Total deferred		132,156			(2,507,355	)
	Total income taxes	$	160,111		$	(2,370,482	)
Schedule of Income Tax Reconciliation	'
		2013						2012
	Tax benefit at federal statutory rate	$	(8,093,340	)		34	%	$	(4,909,912	)	34	%
	State tax, net of federal benefit		(750,351	)		3.2			(578,855	)	4
	Foreign tax		74,612			(0.3	)		-		-
	Nondeductible expenses		637,797			(2.7	)		781,791		(5.4	)
	Other		(50,860	)		0.2			(220,266	)	1.5
	Change in valuation allowance		8,342,253			(35.1	)		2,556,760		(17.7	)
	Income taxes	$	160,111			(0.7	%)	$	(2,370,482	)	16.4	%
Schedule of Deferred Tax Assets and Liabilities	'
		December 31,
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards	$	17,327,134		$	10,077,826
	Equity based compensation		1,281,192			798,701
	Allowance for sales deductions		165,142			182,002
	Amortization of identified intangibles		1,698,913			1,698,492
	Inventory adjustments		619,189			689,307
	Other		776,549			502,479
	Deferred tax assets		21,868,119			13,948,807
	Deferred tax liabilities:
	Prepaid expenses		(152,489	)		(135,914	)
	Goodwill		(1,181,379	)		(1,027,760	)
	Depreciation		(299,541	)		(192,438	)
	Indentified Intangibles		(2,780,224	)		(3,365,512	)
	Other		(654	)		(552	)
	Deferred tax liabilities		(4,414,287	)		(4,722,176	)
	Valuation allowance		(19,119,723	)		(10,777,470	)
	Net deferred tax liabilities	$	(1,665,891	)	$	(1,550,839	)

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies [Abstract]	'
Schedule of Future Minimum Lease Payments	'
	Minimum Future Rental Payments
	Year Ending December 31,	Amount
	2014	$	1,289,799
	2015		1,043,225
	2016		940,565
	2017		804,561
	2018		490,598
	Thereafter		4,014
	Net minimum future rental payments	$	4,572,762

Description_of_Business_Detail

Description of Business (Details)	12 Months Ended
	Dec. 31, 2013
Description of Business [Abstract]	'
Number of operating segments	3

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Summary of Significant Accounting Policies [Abstract]	'	'
FDIC Insured limits	$250,000	'
Advertising and promotion costs	3,082,221	2,243,387
Royalty expense	$1,741,742	$1,395,567
Minimum [Member]	'	'
Depreciation and Amortization, Useful Life [Line Items]	'	'
Equipment and improvements	'3 years	'
Identifiable intangible assets	'1 year	'
Maximum [Member]	'	'
Depreciation and Amortization, Useful Life [Line Items]	'	'
Equipment and improvements	'10 years	'
Identifiable intangible assets	'13 years	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Summary of Foreign Currency (Income) Expense) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Foreign Currency Transactions [Line Items]	'	'
Foreign currency (income) expense	($140,721)	($47,738)
Cost of sales [Member]	'	'
Foreign Currency Transactions [Line Items]	'	'
Foreign currency (income) expense	57,894	7,031
Other income, net [Member]	'	'
Foreign Currency Transactions [Line Items]	'	'
Foreign currency (income) expense	($198,615)	($54,769)

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Potentially Dilutive Shares Excluded as Result of Effects Being Anti-dilutive) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Excluded dilutive shares	4,962,541	5,430,371
Convertible preferred stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Excluded dilutive shares	73,332	73,332
Additional stock issuable related to conversion of preferred stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Excluded dilutive shares	49,154	'
Restricted share units [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Excluded dilutive shares	720,550	786,900
Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Excluded dilutive shares	1,814,233	1,639,985
Warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Excluded dilutive shares	2,305,272	2,930,154

Acquisition_Preliminary_Alloca

Acquisition (Preliminary Allocation of Purchase Price to Estimated Fair Values of Assets Acquired and Liabilities Assumed) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Apr. 17, 2012
Acquisition [Abstract]	'	'	'
Current assets	'	'	$925,817
Equipment	'	'	29,579
Acquired intangible assets	'	'	10,700,000
Goodwill	13,457,693	13,457,693	6,337,967
Total assets acquired	'	'	17,993,363
Current liabilities	'	'	653,315
Deferred tax liability	'	'	2,982,470
Total liabilities assumed	'	'	3,635,785
Net assets acquired	'	'	14,357,578
Purchase price	'	14,475,000	'
Less cash acquired	'	117,422	'
Net cash paid	'	14,357,578	'
Transaction and transition related costs	'	$1,256,853	'

Acquisition_Combined_Results_o

Acquisition (Combined Results of Operations as if Acquisition Had Occurred at Beginning of Period) (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Acquisition [Abstract]	'
Net Sales	$74,035,688
Net Loss	($12,762,551)
Net Loss per common share - basic and diluted	($1.02)
Weighted average number of shares - basic and diluted	12,488,263

Cash_and_Cash_Equivalents_and_2

Cash and Cash Equivalents and Investments (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash and Cash Equivalents and Investments [Abstract]	'	'
Equity securities	2,272,277	'
Ownership percentage	7.30%	'
Payments to acquire equity securities	$7,000,000	'
Fair value of equity investment	6,862,140	'
Unrealized loss recorded in accumulated other comprehensive income	137,860	'
Dividend income	$75,421	'

Cash_and_Cash_Equivalents_and_3

Cash and Cash Equivalents and Investments (Schedule of Cash and Cash Equivalents and Investments) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash and Cash Equivalents and Investments [Abstract]	'	'	'
Cash	$5,265,903	$4,909,663	'
Money market mutual funds	1,235,683	36,706,994	'
Cash and cash equivalents	6,501,586	41,616,657	17,110,350
Investments in debt securities	16,474,000	4,228,000	'
Investment in equity securities	6,862,140	'	'
Total investments	23,336,140	4,228,000	'
Total cash and cash equivalents and investments	$29,837,726	$45,844,657	'

Cash_and_Cash_Equivalents_and_4

Cash and Cash Equivalents and Investments (Fair Value of Cash and Cash Equivalents and Investments) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	$6,501,586	$41,616,657
Investments in debt securities	16,474,000	4,228,000
Investment in equity securities	6,862,140	'
Total Investments	23,336,140	'
Total	29,837,726	45,844,657
Quoted prices in active markets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	6,501,586	41,616,657
Investments in debt securities	16,463,473	4,216,156
Investment in equity securities	6,862,140	'
Total Investments	23,325,613	'
Total	29,827,199	45,832,813
Significant other observable inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	'	'
Investments in debt securities	'	'
Investment in equity securities	'	'
Total Investments	'	'
Total	'	'
Significant unobservable inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash and cash equivalents	'	'
Investments in debt securities	'	'
Investment in equity securities	'	'
Total Investments	'	'
Total	'	'

Accounts_Receivable_net_Detail

Accounts Receivable, net (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accounts Receivable, net [Abstract]	'	'
Accounts receivable	$7,781,482	$7,557,862
Allowance for doubtful accounts	-97,729	-147,843
Allowance for trade rebates	-218,700	-197,650
Allowance for cash discounts and returns	-132,297	-126,656
Accounts receivable, net	$7,332,756	$7,085,713

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Inventories [Abstract]	'	'
Finished goods	$11,044,746	$9,574,685
Work in process	1,009,315	554,129
Packaging materials	1,408,521	991,157
Raw materials	3,010,058	2,550,617
Total inventory	$16,472,640	$13,670,588

Equipment_and_Improvements_net2

Equipment and Improvements, net (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Equipment and improvements	$10,314,523	$10,204,885
Less: accumulated depreciation	-7,361,054	-6,900,033
Total equipment and improvements, net	2,953,469	3,304,852
Machinery and equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Equipment and improvements	7,102,144	7,135,714
Furniture and fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Equipment and improvements	911,879	843,149
Leasehold improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Equipment and improvements	$2,300,500	$2,226,022

Identifiable_Intangible_Assets2

Identifiable Intangible Assets, net (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Development technology [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Acquired intangible assets	$250,000
NCIC International Agreement [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Acquired intangible assets	$100,000

Identifiable_Intangible_Assets3

Identifiable Intangible Assets, net (Schedule of Intangible Assets) (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Minimum [Member]

Maximum [Member]

Product license rights [Member]

Product license rights [Member]

Product license rights [Member]

Product license rights [Member]

Developed technology and supply agreements [Member]

Developed technology and supply agreements [Member]

Developed technology and supply agreements [Member]

Developed technology and supply agreements [Member]

Other [Member]

Other [Member]

Other [Member]

Other [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Indentifiable intangible assets

$22,317,126

$21,967,126

'

'

$8,217,126

$7,967,126

'

'

$7,700,000

$7,600,000

'

'

$6,400,000

$6,400,000

'

'

Less accumulated amortization

-7,681,128

-4,838,243

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total identifiable intangible assets, net

$14,635,998

$17,128,883

'

'

$5,721,055

'

'

'

$5,830,238

'

'

'

$3,084,705

'

'

'

Amortization period

'

'

'1 year

'13 years

'

'

'6 years

'10 years

'

'

'5 years

'7 years

'

'

'1 year

'10 years

Identifiable_Intangible_Assets4

Identifiable Intangible Assets, net (Schedule of Amortization Expense) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization expense	$2,842,885	$2,274,161
Cost of sales [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization expense	2,009,472	1,461,411
Selling, general and administrative expenses [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization expense	$833,413	$812,750

Identifiable_Intangible_Assets5

Identifiable Intangible Assets, net (Schedule of Future Amortization Expense) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization expense	$2,842,885	$2,274,161
Weighted Average Useful Life	'4 years 9 months 18 days	'
Estimated amortization expense for years ending December 31,	'	'
2014	2,827,328	'
2015	2,827,328	'
2016	2,678,578	'
2017	2,333,995	'
2018	2,136,908	'
Thereafter	1,831,861	'
Total identifiable intangible assets, net	14,635,998	17,128,883
Product license rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization expense	908,758	692,363
Weighted Average Useful Life	'6 years	'
Estimated amortization expense for years ending December 31,	'	'
2014	946,613	'
2015	946,613	'
2016	946,613	'
2017	946,613	'
2018	946,613	'
Thereafter	987,990	'
Total identifiable intangible assets, net	5,721,055	'
Developed technology and supply agreements [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization expense	1,100,714	769,048
Weighted Average Useful Life	'5 years 3 months 18 days	'
Estimated amortization expense for years ending December 31,	'	'
2014	1,105,715	'
2015	1,105,715	'
2016	1,105,715	'
2017	1,105,715	'
2018	1,025,295	'
Thereafter	382,083	'
Total identifiable intangible assets, net	5,830,238	'
Other [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Amortization expense	833,413	812,750
Weighted Average Useful Life	'3 years 2 months 12 days	'
Estimated amortization expense for years ending December 31,	'	'
2014	775,000	'
2015	775,000	'
2016	626,250	'
2017	281,667	'
2018	165,000	'
Thereafter	461,788	'
Total identifiable intangible assets, net	$3,084,705	'

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accrued Expenses and Other Current Liabilities [Abstract]	'	'
Accrued compensation and related taxes	$2,529,211	$1,929,524
Accrued Canadian sales rebate, net (note 14)	252,671	636,633
Accrued royalties	361,559	427,075
Accrued sales incentives and other fees	546,296	316,209
Other	1,279,488	823,493
Total accrued expenses and other current liabilities	$4,969,225	$4,132,934

Stockholders_Equity_Preferred_

Stockholders' Equity (Preferred and Common Stock) (Details) (USD $)	0 Months Ended		12 Months Ended
	Dec. 05, 2012	Apr. 05, 2012	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity [Abstract]	'	'	'	'
Common stock, shares authorized	'	'	35,000,000	25,000,000
Shares issued during the period	'	'	822,348	'
Issuance of common stock, net of issuance costs	'	'	'	$51,461,053
Issuance of common stock, issuance costs	'	'	'	4,605,439
Issuance of common stock, net of issuance costs, shares	3,521,300	2,125,000	'	5,646,300
Common stock, price per share	$10.34	$9.25	'	'
Shares of common stock issued upon the exercise of stock purchase warrants and options	'	'	556,855	255,210
Amount received upon the exercise of stock purchase warrants and options	'	'	2,817,001	1,225,620
Issuance costs associated with the exercise of stock purchase warrants and options	'	'	$45,368	$10,560
Common stock issuable upon conversion of preferred stock	'	'	121,089	'
Additional shares issuable	'	'	47,757	'
Shares issued for preferred stock adjustments, per previous shareholder	'	'	1,397	'
Shares issued for preferred stock adjustments	'	'	140,086	'
Shares issued for restricted common stock units	'	'	120,957	43,081
Shares withheld in satisfaction of employee tax withholding obligations	'	'	145,650	'
Issuance of common stock in exchange for services rendered	'	'	4,450	2,500
Class of Stock [Line Items]	'	'	'	'
Convertible preferred stock, shares outstanding	'	'	73,332	73,332
Series A Convertible Preferred Stock [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Convertible preferred stock, shares outstanding	'	'	18,598	'
Liquidation preference per share	'	'	$32	'
Series B Convertible Preferred Stock [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Convertible preferred stock, shares outstanding	'	'	54,734	'
Liquidation preference per share	'	'	$48	'

Stockholders_Equity_Stock_Purc

Stockholders' Equity (Stock Purchase Warrants) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]	'	'
Number of Warrants	2,305,272	'
Warrants exercised	624,882	135,548
Shares issued for warrants exercised	421,465	135,548
J [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants exercised	200,893	66,965
K [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants exercised	367,814	21,250
L [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Number of Warrants	6,250	'
Exercise Price	3.12	'
Expiration Date	31-Mar-14	'
N [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Number of Warrants	100,000	'
Exercise Price	6.25	'
Expiration Date	22-Feb-15	'
O [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Number of Warrants	230,900	'
Exercise Price	5.5	'
Expiration Date	22-Feb-15	'
Warrants exercised	53,667	47,333
P [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Number of Warrants	2,187	'
Exercise Price	6.25	'
Expiration Date	16-Feb-15	'
Warrants exercised	2,508	'
Q [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Number of Warrants	133,333	'
Exercise Price	5.5	'
Expiration Date	22-Feb-15	'
R [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Number of Warrants	1,832,602	'
Exercise Price	9.9	'
Expiration Date	22-Jun-16	'

Stockholders_Equity_Equity_Bas

Stockholders' Equity (Equity Based Compensation) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 05, 2012	Apr. 05, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Number of shares authorized	4,500,000	'	'	'	'
Number of shares available for grant	1,394,480	'	'	'	'
Outstanding options to purchase shares	1,814,233	1,639,985	'	'	1,582,683
Outstanding restricted share units	720,550	786,900	'	'	51,500
Expiration period	'10 years	'	'	'	'
Options granted	421,480	268,160	'	'	'
Common stock, price per share	'	'	$10.34	$9.25	'
Units granted	79,300	786,900	'	'	'
Weighted average fair value per share of units granted	$13.65	$8.78	'	'	'
Shares withheld in satisfaction of employee tax withholding obligations	145,650	'	'	'	'
Fair value of shares withheld in satisfaction of employee tax withholding obligations	$228,149	$80,550	'	'	'
Board of Directors [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Units granted	38,200	24,000	'	'	'
Fair value	525,632	'	'	'	'
Weighted average fair value per share of units granted	$13.76	'	'	'	'
Vesting period	'1 year	'1 year	'	'	'
Employees and Board of Directors [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Fair value	'	459,205	'	'	'
Employees [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Units granted	'	405,000	'	'	'
Fair value	'	2,904,700	'	'	'
Weighted average fair value per share of units granted	'	$7.17	'	'	'
Vesting period	'	'3 years	'	'	'
Retiring director [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Expiration period	'	'36 months	'	'	'
Stock option compensation expense	'	137,393	'	'	'
Shares issued for services	'	2,500	'	'	'
Former director [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Units granted	5,000	'	'	'	'
Shares issued for services	4,450	'	'	'	'
Stock options [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Shares issued for options exercised	135,390	149,033	'	'	'
Outstanding, intrinsic value	6,287,268	'	'	'	'
Exercisable, intrinsic value	5,967,544	'	'	'	'
Common stock, price per share	$10.82	'	'	'	'
Exercised, intrinsic value	1,286,818	792,315	'	'	'
Stock option compensation expense	2,349,134	1,613,347	'	'	'
Unrecognized compensation cost	1,645,272	'	'	'	'
Unrecognized compensation cost, period for recognition	'1 year 10 months 28 days	'	'	'	'
Restricted share units [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Nonvested, intrinsic value	7,796,351	'	'	'	'
Stock option compensation expense	2,634,340	490,870	'	'	'
Unrecognized compensation cost	4,702,124	'	'	'	'
Unrecognized compensation cost, period for recognition	'2 years 1 month 10 days	'	'	'	'
Shares withheld in satisfaction of employee tax withholding obligations	24,693	8,419	'	'	'
Fair value of shares withheld in satisfaction of employee tax withholding obligations	228,149	80,550	'	'	'
Restricted share units [Member] | Retiring director [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Expiration period	'36 months	'	'	'	'
Shares issued for services	5,000	'	'	'	'
Service based options [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Options granted	300,880	199,460	'	'	'
Weighted average fair value per share of options granted	$8.30	$5.93	'	'	'
Units granted	10,000	330,000	'	'	'
Fair value	198,000	3,544,200	'	'	'
Weighted average fair value per share of units granted	'	$10.74	'	'	'
Vesting period	'1 year	'4 years	'	'	'
Vesting rate	25.00%	25.00%	'	'	'
Performance based options [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Options granted	120,600	68,700	'	'	'
Weighted average fair value per share of options granted	$8.30	$5.93	'	'	'
Units granted	26,100	27,900	'	'	'
Fair value	359,136	'	'	'	'
Weighted average fair value per share of units granted	$13.76	'	'	'	'
Vesting period	'	'1 year	'	'	'
Prior service awards [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Stock option compensation expense	$337,422	$137,393	'	'	'

Stockholders_Equity_Weighted_A

Stockholders' Equity (Weighted Average Assumptions Used in Estimation of Fair Value of Option Awards) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity [Abstract]	'	'
Risk free interest rate	1.22%	1.11%
Volatility factor	69.90%	73.60%
Dividend yield	0.00%	0.00%
Expected option life (years)	'6 years 1 month 21 days	'6 years 3 months
Forfeiture rate	1.00%	1.00%

Stockholders_Equity_Summary_of

Stockholders' Equity (Summary of Stock Option Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Number of Shares	'	'
Outstanding - beginning of year	1,639,985	1,582,683
Granted	421,480	268,160
Forfeited	-36,878	-61,825
Exercised	-184,824	-149,033
Expired	-25,530	'
Outstanding - end of year	1,814,233	1,639,985
Expected to vest - end of year	1,796,091	1,623,585
Exercisable at end of year	1,443,409	1,208,077
Weighted Average Exercise Price Per Share	'	'
Outstanding - beginnig of year	$6.38	$5.82
Granted	$12.14	$8.93
Forfeited	$10.99	$7.53
Exercised	$5.50	$4.37
Expired	$13.16	'
Outstanding - end of year	$7.67	$6.38
Expected to vest - end of year	$7.67	$6.38
Exercisable at end of year	$6.84	$5.86

Shareholders_Equity_Summary_of

Shareholders' Equity (Summary of Options Outstanding and Exercisable by Exercise Price Range) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Prices, minimum	$2.88
Exercise Prices, maximum	$13.99
Number Outstanding	1,814,233
Weighted-Average Remaining Contractual Life	'6 years 4 months 10 days
Weighted-Average Exercise Price	$7.67
Number Exercisable	1,443,409
Weighted Average Exercise Price	$6.84
$2.88 - $4.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Prices, minimum	$2.88
Exercise Prices, maximum	$4
Number Outstanding	251,961
Weighted-Average Remaining Contractual Life	'3 years 4 months 17 days
Weighted-Average Exercise Price	$3.43
Number Exercisable	251,961
Weighted Average Exercise Price	$3.43
$4.01 - $6.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Prices, minimum	$4.01
Exercise Prices, maximum	$6
Number Outstanding	473,412
Weighted-Average Remaining Contractual Life	'5 years 2 months 5 days
Weighted-Average Exercise Price	$5.13
Number Exercisable	463,912
Weighted Average Exercise Price	$5.13
$6.01 - $10.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Prices, minimum	$6.01
Exercise Prices, maximum	$10
Number Outstanding	610,470
Weighted-Average Remaining Contractual Life	'6 years 9 months 7 days
Weighted-Average Exercise Price	$8.03
Number Exercisable	500,799
Weighted Average Exercise Price	$7.95
$10.01 - $13.99 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise Prices, minimum	$10.01
Exercise Prices, maximum	$13.99
Number Outstanding	478,390
Weighted-Average Remaining Contractual Life	'8 years 7 months 2 days
Weighted-Average Exercise Price	$11.97
Number Exercisable	226,737
Weighted Average Exercise Price	$11.66

Stockholders_Equity_Allocation

Stockholders' Equity (Allocation of Stock Option Compensation Expense) (Details) (Stock options [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock option compensation expense	$2,349,134	$1,613,347
Cost of sales [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock option compensation expense	95,726	39,789
Selling, general and administrative expenses [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock option compensation expense	2,087,827	1,470,269
Research and development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock option compensation expense	$165,581	$103,289

Stockholders_Equity_Summary_of1

Stockholders' Equity (Summary of Restricted Share Unit Activity) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Number of Shares	'	'
Unvested - beginning of year	786,900	51,500
Granted	79,300	786,900
Vested	-145,650	-51,500
Unvested - end of year	720,550	786,900
Weighted Average Fair Value	'	'
Unvested - beginning of year	$8.78	$7.07
Granted	$13.65	$8.78
Vested	$10.18	$7.07
Unvested - end of year	$9.03	$8.78

Stockholders_Equity_Common_Sto

Stockholders' Equity (Common Stock Shares Reserved for Future Issuance) (Details)	Dec. 31, 2013
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	6,357,021
Convertible preferred shares [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	73,332
Additional stock issuable related to conversion of preferred stock [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	49,154
Common stock options outstanding [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	1,814,233
Common stock warrants outstanding [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	2,305,272
Restricted share units outstanding [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	720,550
Common stock equivalents available for grant [Member]	'
Class of Stock [Line Items]	'
Common stock shares reserved for future issuance	1,394,480

Operating_Segments_Narrative_D

Operating Segments (Narrative) (Details)	12 Months Ended
	Dec. 31, 2013
Operating Segments [Abstract]	'
Number of operating segments	3

Operating_Segments_Schedule_of

Operating Segments (Schedule of Operating Segment Sales, Gross Profit, Segment Contribution and Other Related Information) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Apr. 17, 2012
Segment Reporting Information [Line Items]	'	'	'
Net sales	$79,710,980	$72,648,198	'
Gross profit	29,390,474	25,140,849	'
Direct expense	-37,897,743	-29,083,296	'
Segment contribution	-8,507,269	-3,942,447	'
Indirect expenses	-15,456,784	-8,127,984	'
Net Loss	-23,964,053	-12,070,431	'
Depreciation	878,151	1,021,402	'
Amortization expense	2,842,885	2,274,161	'
Equipment and improvements, net	2,953,469	3,304,852	'
Identifiable intangible assets, net	14,635,998	17,128,883	'
Goodwill	13,457,693	13,457,693	6,337,967
Advanced Wound Care [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	33,928,535	24,832,722	'
Gross profit	16,837,797	12,458,920	'
Direct expense	-21,404,045	-17,658,759	'
Segment contribution	-4,566,248	-5,199,839	'
Depreciation	477,118	629,466	'
Amortization expense	2,557,805	1,950,161	'
Equipment and improvements, net	2,188,389	2,194,498	'
Identifiable intangible assets, net	13,614,210	15,822,016	'
Goodwill	6,337,967	6,337,967	'
Traditional Wound Care [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	45,782,445	47,815,476	'
Gross profit	12,552,677	12,681,929	'
Direct expense	-5,059,141	-4,246,714	'
Segment contribution	7,493,536	8,435,215	'
Depreciation	264,841	246,780	'
Amortization expense	285,080	324,000	'
Equipment and improvements, net	562,480	708,653	'
Identifiable intangible assets, net	1,021,788	1,306,867	'
Goodwill	7,119,726	7,119,726	'
Pharmaceutical Wound Care [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	'	'	'
Gross profit	'	'	'
Direct expense	-11,434,557	-7,177,823	'
Segment contribution	-11,434,557	-7,177,823	'
Depreciation	'	'	'
Amortization expense	'	'	'
Equipment and improvements, net	'	'	'
Identifiable intangible assets, net	'	'	'
Goodwill	'	'	'
Other [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Net sales	'	'	'
Gross profit	'	'	'
Direct expense	'	'	'
Segment contribution	'	'	'
Indirect expenses	-15,456,784	-8,127,984	'
Depreciation	136,192	145,156	'
Amortization expense	'	'	'
Equipment and improvements, net	202,600	401,701	'
Identifiable intangible assets, net	'	'	'
Goodwill	'	'	'

Operating_Segments_Schedule_of1

Operating Segments (Schedule of Sales, Gross Profit and Net Equipment and Improvements) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Net sales	$79,710,980	$72,648,198
Gross profit	29,390,474	25,140,849
Equipment and improvements, net	2,953,469	3,304,852
Unites States [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Net sales	61,234,755	51,325,289
Gross profit	23,956,554	18,609,115
Equipment and improvements, net	459,859	390,925
Canada [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Net sales	11,084,430	14,758,829
Gross profit	2,371,054	3,747,557
Equipment and improvements, net	2,258,544	2,610,462
Other [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Net sales	7,391,795	6,564,080
Gross profit	3,062,866	2,784,177
Equipment and improvements, net	$235,066	$303,465

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]	'	'
Income tax expense	$160,111	($2,370,482)
Current tax expense	27,955	136,873
Deferred tax expense	132,156	-2,507,355
Change in valuation allowance	8,342,253	2,556,760
Net deferred tax liability	-1,665,891	-1,550,839
Net noncurrent deferred tax liability	1,694,147	'
Net current deferred tax asset	28,256	'
Goodwill net deferred tax liability	1,181,379	1,027,760
Intangible assets deferred liability	2,780,224	3,365,512
Research and development tax credit [Member]	'	'
Income Taxes [Line Items]	'	'
Tax credit carryforwards	1,015,000	'
US [Member]	'	'
Income Taxes [Line Items]	'	'
Income tax expense	120,330	'
Current tax expense	5,365	'
Deferred tax expense	114,965	'
Tax treatment of goodwill	153,619	'
Amortization of intangible assets	38,654	'
Goodwill net deferred tax liability	1,181,379	'
Intangible assets deferred liability	225,309	'
Foreign net deferred tax liability	259,203	'
Net operating loss carry forwards	46,343,000	'
Foreign [Member]	'	'
Income Taxes [Line Items]	'	'
Income tax expense	39,781	'
Tax credit carryforwards	$179,000	'

Income_Taxes_Schedule_of_Loss_

Income Taxes (Schedule of Loss Before Income Taxes) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Abstract]	'	'
Domestic	($23,145,554)	($14,590,416)
Foreign	-658,388	149,503
Loss before income taxes	($23,803,942)	($14,440,913)

Income_Taxes_Schedule_of_Incom

Income Taxes (Schedule of Income Tax (Benefit)) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Current:	'	'
Federal	'	'
State	5,365	'
Foreign	22,590	136,873
Total current	27,955	136,873
Deferred:	'	'
Federal	149,108	-2,291,057
State	-34,143	-219,463
Foreign	17,191	3,165
Total deferred	132,156	-2,507,355
Income taxes	$160,111	($2,370,482)

Income_Taxes_Reconciliation_of

Income Taxes (Reconciliation of Income Tax) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Reconciliation	'	'
Tax benefit at federal statutory rate	($8,093,340)	($4,909,912)
State tax, net of federal benefit	-750,351	-578,855
Foreign tax	74,612	'
Nondeductible expenses	637,797	781,791
Other	-50,860	-220,266
Change in valuation allowance	8,342,253	2,556,760
Income taxes	$160,111	($2,370,482)
Income Tax Rate Reconciliation	'	'
Tax benefit at federal statutory rate, rate	34.00%	34.00%
State tax, net of federal benefit	3.20%	4.00%
Foreign tax	-0.30%	'
Nondeductable expenses	-2.70%	-5.40%
Other	0.20%	1.50%
Change in valuation allowance	-35.10%	-17.70%
Income taxes	-0.70%	16.40%

Income_Taxes_Schedule_of_Defer

Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Net operating loss carryforwards	$17,327,134	$10,077,826
Equity based compensation	1,281,192	798,701
Allowance for sales deductions	165,142	182,002
Amortization of identified intangibles	1,698,913	1,698,492
Inventory adjustments	619,189	689,307
Other	776,549	502,479
Deferred tax assets	21,868,119	13,948,807
Deferred tax liabilities:	'	'
Prepaid expenses	-152,489	-135,914
Goodwill	-1,181,379	-1,027,760
Depreciation	-299,541	-192,438
Indentified Intangibles	-2,780,224	-3,365,512
Other	-654	-552
Deferred tax liabilities	-4,414,287	-4,722,176
Valuation allowance	-19,119,723	-10,777,470
Net deferred tax liabilities	($1,665,891)	($1,550,839)

Retirement_Benefits_Details

Retirement Benefits (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Defined Benefit Plan Disclosure [Line Items]	'	'
Employer matching percentage	100.00%	100.00%
percentage of participant's contributed annual base salary	4.00%	4.00%
Contributions by company	$303,913	$208,654
Canadian subsidiary [Member]	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'
Employer matching percentage	100.00%	100.00%
percentage of participant's contributed annual base salary	4.00%	4.00%
Contributions by company	$133,319	$109,442

Commitments_and_Contingencies_1

Commitments and Contingencies (Operating Leases) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Commitments and Contingencies [Abstract]	'	'
Lease expense	$1,227,718	$1,544,575
Deferred rent	242,325	268,517
Minimum Future Rental Payments	'	'
2013	1,289,799	'
2014	1,043,225	'
2015	940,565	'
2016	804,561	'
2017	490,598	'
Thereafter	4,014	'
Net minimum future rental payments	$4,572,762	'

Commitments_and_Contingencies_2

Commitments and Contingencies (Agreements) (Details) (USD $)	12 Months Ended			47 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Licensing Agreements [Line Items]	'	'	'	'
Royalties	$1,741,742	$1,395,567	'	'
Payments to acquire equity securities	7,000,000	'	'	'
Comvita Agreement [Member]	'	'	'	'
Licensing Agreements [Line Items]	'	'	'	'
Milestone sales	'	10,000,000	'	'
Maximum milestone payments	20,000,000	'	'	20,000,000
Cash paid for agreement	'	1,000,000	1,000,000	2,000,000
Purchases from related party	2,266,964	1,653,075	'	'
Due to related party	421,578	288,596	'	421,578
Royalties	1,240,818	901,826	'	'
QMT Agreement [Member]	'	'	'	'
Licensing Agreements [Line Items]	'	'	'	'
Maximum milestone payments	3,500,000	'	'	3,500,000
Royalties	202,377	279,537	'	'
Initial fee	'	1,300,000	'	'
Amortization period	'	'7 years	'	'
USC Agreement [Member]	'	'	'	'
Licensing Agreements [Line Items]	'	'	'	'
Maximum milestone payments	9,625,000	'	'	9,625,000
Royalties payable, revenue threshold	100,000,000	'	'	'
NCIC International Agreement [Member]	'	'	'	'
Licensing Agreements [Line Items]	'	'	'	'
Maximum milestone payments	1,000,000	'	'	1,000,000
Cash paid for agreement	200,000	'	'	'
Refundable deposit	100,000	'	'	100,000
Initial fee	$100,000	'	'	'
Amortization period	'5 years	'	'	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	0 Months Ended		12 Months Ended		0 Months Ended			1 Months Ended
	Dec. 05, 2012	Apr. 05, 2012	Dec. 31, 2013	Dec. 31, 2012	Jan. 14, 2014	Jan. 14, 2014	Jan. 14, 2014	Jan. 29, 2014
					BioDLogics, LLC [Member]	BioDLogics, LLC [Member]	BioDLogics, LLC [Member]	Subsequent Event [Member]
						Immediately [Member]	Milestones [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'	'
Initial fee	'	'	'	'	$1,250,000	'	'	'
Number of shares called by warrants	'	'	'	'	100,000	'	'	'
Exercise price	'	'	'	'	11.81	'	'	'
Vesting rate	'	'	'	'	'	25.00%	75.00%	'
Expiration period	'	'	'10 years	'	'5 years	'	'	'
Maximum milestone payments	'	'	'	'	19,750,000	'	'	'
Proceeds from sale of common stock	'	'	'	51,461,053	'	'	'	80,675,000
Payments for commission and other offering expenses	'	'	'	'	'	'	'	$5,575,000
Issuance of common stock	3,521,300	2,125,000	'	5,646,300	'	'	'	7,500,000
Price per share	$10.34	$9.25	'	'	'	'	'	$11.50